{"id":9986,"date":"2026-11-03T11:16:38","date_gmt":"2026-11-03T11:16:38","guid":{"rendered":"https:\/\/sustainability.uoa.edu.iq\/index.php\/sustainability-impact-network\/sdg-research-keywords\/sdg-03-research-keywords\/"},"modified":"2026-11-03T11:22:22","modified_gmt":"2026-11-03T11:22:22","slug":"sdg-03-research-keywords","status":"publish","type":"page","link":"https:\/\/sustainability.uoa.edu.iq\/index.php\/sustainability-impact-network\/sdg-research-keywords\/sdg-03-research-keywords\/","title":{"rendered":"SDG 3: Good Health and Well-being \u2014 Research Keywords"},"content":{"rendered":"\n<div class=\"ds-page ds-gen-page\" style=\"--sdg:#4C9F38\"><header class=\"ds-hero\" style=\"--sdg:#4C9F38\"><nav class=\"ds-crumbs\" aria-label=\"Breadcrumb\"><a href=\"https:\/\/sustainability.uoa.edu.iq\/\">Home<\/a><span class=\"sep\">\/<\/span><span>Ranking<\/span><span class=\"sep\">\/<\/span><a href=\"https:\/\/sustainability.uoa.edu.iq\/index.php\/sustainability-impact-network\/\">Sustainability Impact Network<\/a><span class=\"sep\">\/<\/span><a href=\"https:\/\/sustainability.uoa.edu.iq\/index.php\/sustainability-impact-network\/sdg-research-keywords\/\">SDG Research Keywords<\/a><span class=\"sep\">\/<\/span><span>SDG 3<\/span><\/nav><div class=\"ds-badge\"><b>3<\/b>Good Health and Well-being<\/div><h1>SDG 3: Good Health and Well-being \u2014 Research Keywords<\/h1><p class=\"lead\">Research keywords that map publications to SDG 3 (Good Health and Well-being), from the Sustainability Research Mapping 2023 lists.<\/p><div class=\"ds-meta\"><span><i class=\"ds-ic\" style=\"--i:url(https:\/\/api.iconify.design\/lucide\/star.svg)\" aria-hidden=\"true\"><\/i> 21 golden<\/span><span><i class=\"ds-ic\" style=\"--i:url(https:\/\/api.iconify.design\/lucide\/list-ordered.svg)\" aria-hidden=\"true\"><\/i> 100 in the Top 100<\/span><span><i class=\"ds-ic\" style=\"--i:url(https:\/\/api.iconify.design\/lucide\/table.svg)\" aria-hidden=\"true\"><\/i> 1,000 in the Top 1,000<\/span><\/div><\/header><nav class=\"ds-chipnav\" aria-label=\"On this page\"><b>On this page<\/b><a href=\"#golden\">Golden list<\/a><a href=\"#top-100\">Top 100<\/a><a href=\"#top-1000\">Top 1,000<\/a><\/nav><section class=\"ds-sec\" id=\"golden\"><div class=\"ds-head\"><div><span class=\"ds-eyebrow\">Golden list<\/span><h2>Golden keywords<\/h2><p>Keywords that identify this goal on their own. A superscript marks other goals that share the keyword.<\/p><\/div><\/div><div class=\"kw-chips\"><span class=\"kw-chip\">antenatal care (anc)<sup>17<\/sup><\/span><span class=\"kw-chip\">cancer disparities<sup>10<\/sup><\/span><span class=\"kw-chip\">high hiv prevalence<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv acquisition<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv diagnosis<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv knowledge<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv prevention intervention<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv risk behavior<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv services<sup>5, 17<\/sup><\/span><span class=\"kw-chip\">hiv stigma<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv\/sti<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv-exposed<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv-positive men<sup>5<\/sup><\/span><span class=\"kw-chip\">hiv-related stigma<sup>5<\/sup><\/span><span class=\"kw-chip\">long-acting reversible<sup>5<\/sup><\/span><span class=\"kw-chip\">men living with hiv<sup>5<\/sup><\/span><span class=\"kw-chip\">mother-to-child transmission of hiv<sup>5<\/sup><\/span><span class=\"kw-chip\">pmtct<sup>5, 17<\/sup><\/span><span class=\"kw-chip\">pre-exposure prophylaxis (prep)<sup>5<\/sup><\/span><span class=\"kw-chip\">prevention of mother-to-child transmission<sup>5, 17<\/sup><\/span><span class=\"kw-chip\">women living with hiv<sup>5<\/sup><\/span><\/div><\/section><section class=\"ds-sec\" id=\"top-100\"><div class=\"ds-head\"><div><span class=\"ds-eyebrow\">Top 100<\/span><h2>Top 100 keywords<\/h2><p>The 100 most relevant keywords for this goal, by rank.<\/p><\/div><\/div><ol class=\"kw-ol\"><li><i>1<\/i><span>allergy, asthma<\/span><\/li><li><i>2<\/i><span>community-acquired pneumonia (cap)<\/span><\/li><li><i>3<\/i><span>metastasis-free survival<\/span><\/li><li><i>4<\/i><span>prostate cancer cell lines<\/span><\/li><li><i>5<\/i><span>cancer quality of life<\/span><\/li><li><i>6<\/i><span>cancer outcomes<\/span><\/li><li><i>7<\/i><span>papillary thyroid carcinoma (ptc)<\/span><\/li><li><i>8<\/i><span>stroke severity<\/span><\/li><li><i>9<\/i><span>egfr-tki<\/span><\/li><li><i>10<\/i><span>cancer resistance<\/span><\/li><li><i>11<\/i><span>asthma exacerbations<\/span><\/li><li><i>12<\/i><span>advanced rectal cancer<\/span><\/li><li><i>13<\/i><span>type 2 diabetes (t2dm)<\/span><\/li><li><i>14<\/i><span>type 1 diabetes mellitus (t1dm)<\/span><\/li><li><i>15<\/i><span>overweight or obesity<\/span><\/li><li><i>16<\/i><span>stroke outcome<\/span><\/li><li><i>17<\/i><span>muscle-invasive bladder cancer<\/span><\/li><li><i>18<\/i><span>hcc cell lines<\/span><\/li><li><i>19<\/i><span>cardiovascular disease (cvd) risk<\/span><\/li><li><i>20<\/i><span>diabetes prevention<\/span><\/li><li><i>21<\/i><span>folfox<\/span><\/li><li><i>22<\/i><span>hiv diagnosis<\/span><\/li><li><i>23<\/i><span>response evaluation criteria in solid tumor<\/span><\/li><li><i>24<\/i><span>mcf-7 breast cancer cells<\/span><\/li><li><i>25<\/i><span>interstitial lung disease (ild)<\/span><\/li><li><i>26<\/i><span>pathological complete response<\/span><\/li><li><i>27<\/i><span>art initiation<\/span><\/li><li><i>28<\/i><span>national comprehensive cancer network<\/span><\/li><li><i>29<\/i><span>combination antiretroviral therapy<\/span><\/li><li><i>30<\/i><span>prostate cancer risk<\/span><\/li><li><i>31<\/i><span>european organization for research and treatment of cancer<\/span><\/li><li><i>32<\/i><span>pc-3 cells<\/span><\/li><li><i>33<\/i><span>xenograft tumors<\/span><\/li><li><i>34<\/i><span>acute ischemic stroke (ais)<\/span><\/li><li><i>35<\/i><span>mouse xenograft model<\/span><\/li><li><i>36<\/i><span>breast cancer subtype<\/span><\/li><li><i>37<\/i><span>stroke care<\/span><\/li><li><i>38<\/i><span>response evaluation criteria in solid tumors<\/span><\/li><li><i>39<\/i><span>cancer cell death<\/span><\/li><li><i>40<\/i><span>obesity risk<\/span><\/li><li><i>41<\/i><span>dengue virus (denv)<\/span><\/li><li><i>42<\/i><span>egfr tyrosine kinase<\/span><\/li><li><i>43<\/i><span>anti-cancer effects<\/span><\/li><li><i>44<\/i><span>sustained virologic response<\/span><\/li><li><i>45<\/i><span>persistent asthma<\/span><\/li><li><i>46<\/i><span>european society for medical oncology<\/span><\/li><li><i>47<\/i><span>national cancer database<\/span><\/li><li><i>48<\/i><span>obesity and insulin resistance<\/span><\/li><li><i>49<\/i><span>cancer resection<\/span><\/li><li><i>50<\/i><span>objective response rate (orr)<\/span><\/li><li><i>51<\/i><span>advanced non-small cell lung cancer (nsclc)<\/span><\/li><li><i>52<\/i><span>cvd event<\/span><\/li><li><i>53<\/i><span>large b cell lymphoma<\/span><\/li><li><i>54<\/i><span>lung cancer screen<\/span><\/li><li><i>55<\/i><span>highly pathogenic avian influenza<\/span><\/li><li><i>56<\/i><span>lung cancer screening<\/span><\/li><li><i>57<\/i><span>epithelial ovarian cancer (eoc)<\/span><\/li><li><i>58<\/i><span>rectal cancer surgery<\/span><\/li><li><i>59<\/i><span>nonsmall cell<\/span><\/li><li><i>60<\/i><span>cancer development and progression<\/span><\/li><li><i>61<\/i><span>sentinel lymph nodes<\/span><\/li><li><i>62<\/i><span>kras mutations<\/span><\/li><li><i>63<\/i><span>hepatitis e virus (hev)<\/span><\/li><li><i>64<\/i><span>neoadjuvant chemotherapy<\/span><\/li><li><i>65<\/i><span>diffuse large b cell<\/span><\/li><li><i>66<\/i><span>non-small cell lung cancer patients<\/span><\/li><li><i>67<\/i><span>multidrug-resistant tuberculosis<\/span><\/li><li><i>68<\/i><span>locally advanced rectal cancer<\/span><\/li><li><i>69<\/i><span>cancer cell invasion<\/span><\/li><li><i>70<\/i><span>hiv viral load<\/span><\/li><li><i>71<\/i><span>metastatic castration-resistant<\/span><\/li><li><i>72<\/i><span>nonsmall cell lung<\/span><\/li><li><i>73<\/i><span>malt lymphoma<\/span><\/li><li><i>74<\/i><span>cancer survivorship<\/span><\/li><li><i>75<\/i><span>advanced hepatocellular carcinoma<\/span><\/li><li><i>76<\/i><span>her2+<\/span><\/li><li><i>77<\/i><span>chronic hepatitis c virus (hcv)<\/span><\/li><li><i>78<\/i><span>chemoradiation therapy<\/span><\/li><li><i>79<\/i><span>suicide ideation<\/span><\/li><li><i>80<\/i><span>cancer drug delivery<\/span><\/li><li><i>81<\/i><span>advanced hcc<\/span><\/li><li><i>82<\/i><span>hcv patients<\/span><\/li><li><i>83<\/i><span>neoadjuvant chemoradiotherapy<\/span><\/li><li><i>84<\/i><span>pharyngeal squamous cell carcinoma<\/span><\/li><li><i>85<\/i><span>hereditary breast<\/span><\/li><li><i>86<\/i><span>controlled asthma<\/span><\/li><li><i>87<\/i><span>pathologic complete response<\/span><\/li><li><i>88<\/i><span>ovarian cancer cell lines<\/span><\/li><li><i>89<\/i><span>cancer gene therapy<\/span><\/li><li><i>90<\/i><span>prostate cancer (pc)<\/span><\/li><li><i>91<\/i><span>hiv-uninfected<\/span><\/li><li><i>92<\/i><span>hepatitis c patients<\/span><\/li><li><i>93<\/i><span>advanced pancreatic cancer<\/span><\/li><li><i>94<\/i><span>cancer-specific mortality<\/span><\/li><li><i>95<\/i><span>adults with type 2 diabetes<\/span><\/li><li><i>96<\/i><span>carcinoma hepatocellular<\/span><\/li><li><i>97<\/i><span>sentinel node biopsy<\/span><\/li><li><i>98<\/i><span>metastatic castration-resistant prostate cancer<\/span><\/li><li><i>99<\/i><span>hiv-1 subtype<\/span><\/li><li><i>100<\/i><span>anti-her2<\/span><\/li><\/ol><\/section><section class=\"ds-sec\" id=\"top-1000\"><div class=\"ds-head\"><div><span class=\"ds-eyebrow\">Top 1,000<\/span><h2>Top 1,000 keywords<\/h2><p>Rank, keyword and its metrics in Scopus.<\/p><\/div><\/div><div class=\"kw-tools\"><input type=\"search\" class=\"kw-q\" placeholder=\"Filter keywords\u2026\" aria-label=\"Filter keywords\u2026\"><small><b class=\"kw-n\">1000<\/b> keywords shown<\/small><\/div><div class=\"ds-table kw-scroll\"><table><thead><tr><th class=\"r\">Rank<\/th><th class=\"\">Keyword<\/th><th class=\"r\">Papers in the SDG set<\/th><th class=\"r\">Papers in all of Scopus<\/th><th class=\"r\">tf-idf<\/th><th class=\"r\">% of Scopus<\/th><\/tr><\/thead><tbody><tr><td class=\"r\">1<\/td><td class=\"k\">national institutes of health stroke scale score<\/td><td class=\"r\">1,802<\/td><td class=\"r\">1,820<\/td><td class=\"r\">19.06<\/td><td class=\"r\">99%<\/td><\/tr><tr><td class=\"r\">2<\/td><td class=\"k\">international association for the study of lung cancer<\/td><td class=\"r\">2,263<\/td><td class=\"r\">2,318<\/td><td class=\"r\">19.05<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">3<\/td><td class=\"k\">stroke thrombectomy<\/td><td class=\"r\">1,715<\/td><td class=\"r\">1,745<\/td><td class=\"r\">19.04<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">4<\/td><td class=\"k\">functional assessment of cancer therapy<\/td><td class=\"r\">2,793<\/td><td class=\"r\">2,864<\/td><td class=\"r\">19.04<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">5<\/td><td class=\"k\">european prospective investigation into cancer<\/td><td class=\"r\">1,617<\/td><td class=\"r\">1,643<\/td><td class=\"r\">19.04<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">6<\/td><td class=\"k\">sustained virological response (svr)<\/td><td class=\"r\">2,512<\/td><td class=\"r\">2,585<\/td><td class=\"r\">19.04<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">7<\/td><td class=\"k\">alcohol use disorders identification test<\/td><td class=\"r\">2,409<\/td><td class=\"r\">2,481<\/td><td class=\"r\">19.04<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">8<\/td><td class=\"k\">diabetes mellitus, type 2<\/td><td class=\"r\">1,543<\/td><td class=\"r\">1,565<\/td><td class=\"r\">19.03<\/td><td class=\"r\">99%<\/td><\/tr><tr><td class=\"r\">9<\/td><td class=\"k\">breast cancer resistance protein<\/td><td class=\"r\">2,388<\/td><td class=\"r\">2,468<\/td><td class=\"r\">19.03<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">10<\/td><td class=\"k\">adolescents with type 1 diabetes<\/td><td class=\"r\">2,576<\/td><td class=\"r\">2,665<\/td><td class=\"r\">19.03<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">11<\/td><td class=\"k\">national cancer database<\/td><td class=\"r\">3,669<\/td><td class=\"r\">3,725<\/td><td class=\"r\">19.02<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">12<\/td><td class=\"k\">hiv\/hcv<\/td><td class=\"r\">2,128<\/td><td class=\"r\">2,205<\/td><td class=\"r\">19.02<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">13<\/td><td class=\"k\">kaposi&#8217;s sarcoma-associated herpesvirus<\/td><td class=\"r\">2,098<\/td><td class=\"r\">2,176<\/td><td class=\"r\">19.02<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">14<\/td><td class=\"k\">barcelona clinic liver cancer<\/td><td class=\"r\">1,775<\/td><td class=\"r\">1,830<\/td><td class=\"r\">19.02<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">15<\/td><td class=\"k\">european prospective investigation into cancer and nutrition<\/td><td class=\"r\">1,439<\/td><td class=\"r\">1,461<\/td><td class=\"r\">19.02<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">16<\/td><td class=\"k\">distant metastasis-free survival<\/td><td class=\"r\">2,283<\/td><td class=\"r\">2,374<\/td><td class=\"r\">19.02<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">17<\/td><td class=\"k\">breast cancer resistance<\/td><td class=\"r\">2,619<\/td><td class=\"r\">2,720<\/td><td class=\"r\">19.02<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">18<\/td><td class=\"k\">oropharyngeal squamous cell carcinoma<\/td><td class=\"r\">2,566<\/td><td class=\"r\">2,667<\/td><td class=\"r\">19.02<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">19<\/td><td class=\"k\">mda-mb-231 breast cancer cells<\/td><td class=\"r\">2,054<\/td><td class=\"r\">2,135<\/td><td class=\"r\">19.02<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">20<\/td><td class=\"k\">metastatic renal cell carcinoma (mrcc)<\/td><td class=\"r\">1,797<\/td><td class=\"r\">1,859<\/td><td class=\"r\">19.02<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">21<\/td><td class=\"k\">european organisation for research and treatment of cancer<\/td><td class=\"r\">1,831<\/td><td class=\"r\">1,896<\/td><td class=\"r\">19.02<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">22<\/td><td class=\"k\">incident diabetes<\/td><td class=\"r\">1,995<\/td><td class=\"r\">2,073<\/td><td class=\"r\">19.02<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">23<\/td><td class=\"k\">high-risk prostate cancer<\/td><td class=\"r\">1,867<\/td><td class=\"r\">1,936<\/td><td class=\"r\">19.02<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">24<\/td><td class=\"k\">plasma hiv-1 rna<\/td><td class=\"r\">1,437<\/td><td class=\"r\">1,463<\/td><td class=\"r\">19.02<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">25<\/td><td class=\"k\">biochemical failure<\/td><td class=\"r\">2,170<\/td><td class=\"r\">2,260<\/td><td class=\"r\">19.02<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">26<\/td><td class=\"k\">metastatic colorectal cancer (mcrc)<\/td><td class=\"r\">3,188<\/td><td class=\"r\">3,289<\/td><td class=\"r\">19.01<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">27<\/td><td class=\"k\">pathologic complete response (pcr)<\/td><td class=\"r\">1,647<\/td><td class=\"r\">1,698<\/td><td class=\"r\">19.01<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">28<\/td><td class=\"k\">national institutes of health stroke scale (nihss)<\/td><td class=\"r\">3,233<\/td><td class=\"r\">3,333<\/td><td class=\"r\">19.01<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">29<\/td><td class=\"k\">chemoradiotherapy (crt)<\/td><td class=\"r\">2,986<\/td><td class=\"r\">3,093<\/td><td class=\"r\">19.01<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">30<\/td><td class=\"k\">national institute of health stroke scale<\/td><td class=\"r\">1,833<\/td><td class=\"r\">1,902<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">31<\/td><td class=\"k\">prostate-specific membrane antigen (psma)<\/td><td class=\"r\">2,024<\/td><td class=\"r\">2,108<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">32<\/td><td class=\"k\">metastatic castration-resistant prostate cancer (mcrpc)<\/td><td class=\"r\">1,633<\/td><td class=\"r\">1,685<\/td><td class=\"r\">19.01<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">33<\/td><td class=\"k\">pandemic influenza a<\/td><td class=\"r\">2,100<\/td><td class=\"r\">2,191<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">34<\/td><td class=\"k\">colorectal cancer (crc) screening<\/td><td class=\"r\">1,698<\/td><td class=\"r\">1,757<\/td><td class=\"r\">19.01<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">35<\/td><td class=\"k\">mda-mb-231 breast cancer cell<\/td><td class=\"r\">2,626<\/td><td class=\"r\">2,739<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">36<\/td><td class=\"k\">chronic hepatitis c (chc)<\/td><td class=\"r\">2,512<\/td><td class=\"r\">2,624<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">37<\/td><td class=\"k\">metastatic crc<\/td><td class=\"r\">1,922<\/td><td class=\"r\">2,004<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">38<\/td><td class=\"k\">health services accessibility<\/td><td class=\"r\">1,929<\/td><td class=\"r\">2,012<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">39<\/td><td class=\"k\">non\u2013small cell lung<\/td><td class=\"r\">1,979<\/td><td class=\"r\">2,066<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">40<\/td><td class=\"k\">pandemic h1n1<\/td><td class=\"r\">1,809<\/td><td class=\"r\">1,882<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">41<\/td><td class=\"k\">hbv genotype<\/td><td class=\"r\">2,169<\/td><td class=\"r\">2,269<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">42<\/td><td class=\"k\">non\u2013small cell<\/td><td class=\"r\">2,002<\/td><td class=\"r\">2,093<\/td><td class=\"r\">19.01<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">43<\/td><td class=\"k\">cancer and nutrition<\/td><td class=\"r\">1,556<\/td><td class=\"r\">1,605<\/td><td class=\"r\">19.01<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">44<\/td><td class=\"k\">sentinel lymph node biopsy (slnb)<\/td><td class=\"r\">2,140<\/td><td class=\"r\">2,241<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">45<\/td><td class=\"k\">disease-specific survival (dss)<\/td><td class=\"r\">2,757<\/td><td class=\"r\">2,879<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">46<\/td><td class=\"k\">2009 pandemic<\/td><td class=\"r\">2,024<\/td><td class=\"r\">2,118<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">47<\/td><td class=\"k\">substance-related disorder<\/td><td class=\"r\">2,262<\/td><td class=\"r\">2,371<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">48<\/td><td class=\"k\">asthma control test<\/td><td class=\"r\">1,750<\/td><td class=\"r\">1,821<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">49<\/td><td class=\"k\">hcc recurrence<\/td><td class=\"r\">1,900<\/td><td class=\"r\">1,985<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">50<\/td><td class=\"k\">international prognostic index<\/td><td class=\"r\">2,930<\/td><td class=\"r\">3,054<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">51<\/td><td class=\"k\">substance-related disorders<\/td><td class=\"r\">2,106<\/td><td class=\"r\">2,207<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">52<\/td><td class=\"k\">mcrpc<\/td><td class=\"r\">2,717<\/td><td class=\"r\">2,841<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">53<\/td><td class=\"k\">non\u2013small cell lung cancer<\/td><td class=\"r\">1,873<\/td><td class=\"r\">1,957<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">54<\/td><td class=\"k\">a549 lung cancer<\/td><td class=\"r\">1,800<\/td><td class=\"r\">1,878<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">55<\/td><td class=\"k\">tumor-node-metastasis<\/td><td class=\"r\">2,424<\/td><td class=\"r\">2,543<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">56<\/td><td class=\"k\">her2 status<\/td><td class=\"r\">2,540<\/td><td class=\"r\">2,663<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">57<\/td><td class=\"k\">sln biopsy<\/td><td class=\"r\">1,471<\/td><td class=\"r\">1,513<\/td><td class=\"r\">19<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">58<\/td><td class=\"k\">stroke center<\/td><td class=\"r\">2,593<\/td><td class=\"r\">2,718<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">59<\/td><td class=\"k\">global initiative for chronic obstructive lung disease<\/td><td class=\"r\">1,696<\/td><td class=\"r\">1,766<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">60<\/td><td class=\"k\">hcv treatment<\/td><td class=\"r\">3,115<\/td><td class=\"r\">3,245<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">61<\/td><td class=\"k\">non-muscle-invasive<\/td><td class=\"r\">1,833<\/td><td class=\"r\">1,918<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">62<\/td><td class=\"k\">advanced hepatocellular carcinoma (hcc)<\/td><td class=\"r\">1,781<\/td><td class=\"r\">1,861<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">63<\/td><td class=\"k\">hcv genotype 1<\/td><td class=\"r\">2,740<\/td><td class=\"r\">2,873<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">64<\/td><td class=\"k\">neuroblastoma sh-sy5y cell<\/td><td class=\"r\">1,829<\/td><td class=\"r\">1,915<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">65<\/td><td class=\"k\">nsclcs<\/td><td class=\"r\">2,218<\/td><td class=\"r\">2,334<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">66<\/td><td class=\"k\">hiv-uninfected<\/td><td class=\"r\">3,292<\/td><td class=\"r\">3,421<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">67<\/td><td class=\"k\">cancer cell apoptosis<\/td><td class=\"r\">2,425<\/td><td class=\"r\">2,552<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">68<\/td><td class=\"k\">hiv-1 subtype<\/td><td class=\"r\">3,245<\/td><td class=\"r\">3,376<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">69<\/td><td class=\"k\">peripheral artery disease (pad)<\/td><td class=\"r\">2,802<\/td><td class=\"r\">2,938<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">70<\/td><td class=\"k\">pdm09<\/td><td class=\"r\">2,289<\/td><td class=\"r\">2,410<\/td><td class=\"r\">19<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">71<\/td><td class=\"k\">adults with type 2 diabetes<\/td><td class=\"r\">3,260<\/td><td class=\"r\">3,391<\/td><td class=\"r\">19<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">72<\/td><td class=\"k\">metastatic breast cancer (mbc)<\/td><td class=\"r\">2,617<\/td><td class=\"r\">2,751<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">73<\/td><td class=\"k\">epidermal growth factor receptor (egfr) mutation<\/td><td class=\"r\">2,137<\/td><td class=\"r\">2,250<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">74<\/td><td class=\"k\">cancer-specific mortality<\/td><td class=\"r\">3,264<\/td><td class=\"r\">3,396<\/td><td class=\"r\">18.99<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">75<\/td><td class=\"k\">papillary thyroid cancer (ptc)<\/td><td class=\"r\">2,024<\/td><td class=\"r\">2,129<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">76<\/td><td class=\"k\">weekly paclitaxel<\/td><td class=\"r\">1,585<\/td><td class=\"r\">1,647<\/td><td class=\"r\">18.99<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">77<\/td><td class=\"k\">neuroblastoma sh-sy5y<\/td><td class=\"r\">2,012<\/td><td class=\"r\">2,117<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">78<\/td><td class=\"k\">egfr tyrosine kinase inhibitors<\/td><td class=\"r\">1,922<\/td><td class=\"r\">2,020<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">79<\/td><td class=\"k\">shiga toxin-producing escherichia coli<\/td><td class=\"r\">2,557<\/td><td class=\"r\">2,692<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">80<\/td><td class=\"k\">uncontrolled asthma<\/td><td class=\"r\">1,899<\/td><td class=\"r\">1,996<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">81<\/td><td class=\"k\">prostate cancer radiotherapy<\/td><td class=\"r\">1,717<\/td><td class=\"r\">1,796<\/td><td class=\"r\">18.99<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">82<\/td><td class=\"k\">diabetes status<\/td><td class=\"r\">2,912<\/td><td class=\"r\">3,055<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">83<\/td><td class=\"k\">opscc<\/td><td class=\"r\">1,469<\/td><td class=\"r\">1,520<\/td><td class=\"r\">18.99<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">84<\/td><td class=\"k\">european society for medical oncology<\/td><td class=\"r\">3,694<\/td><td class=\"r\">3,816<\/td><td class=\"r\">18.99<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">85<\/td><td class=\"k\">neuroblastoma sh-sy5y cells<\/td><td class=\"r\">1,604<\/td><td class=\"r\">1,673<\/td><td class=\"r\">18.99<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">86<\/td><td class=\"k\">baseline hba1c<\/td><td class=\"r\">1,663<\/td><td class=\"r\">1,739<\/td><td class=\"r\">18.99<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">87<\/td><td class=\"k\">asthma outcome<\/td><td class=\"r\">1,476<\/td><td class=\"r\">1,529<\/td><td class=\"r\">18.99<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">88<\/td><td class=\"k\">a549 lung cancer cell<\/td><td class=\"r\">1,611<\/td><td class=\"r\">1,681<\/td><td class=\"r\">18.99<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">89<\/td><td class=\"k\">neoadjuvant chemoradiation<\/td><td class=\"r\">2,054<\/td><td class=\"r\">2,168<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">90<\/td><td class=\"k\">substance use treatment<\/td><td class=\"r\">1,991<\/td><td class=\"r\">2,100<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">91<\/td><td class=\"k\">chronic hepatitis c virus (hcv) infection<\/td><td class=\"r\">2,586<\/td><td class=\"r\">2,729<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">92<\/td><td class=\"k\">cancer-related fatigue<\/td><td class=\"r\">1,715<\/td><td class=\"r\">1,798<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">93<\/td><td class=\"k\">hbv dna level<\/td><td class=\"r\">2,409<\/td><td class=\"r\">2,546<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">94<\/td><td class=\"k\">stroke thrombolysis<\/td><td class=\"r\">1,490<\/td><td class=\"r\">1,546<\/td><td class=\"r\">18.99<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">95<\/td><td class=\"k\">head and neck cancer (hnc)<\/td><td class=\"r\">3,078<\/td><td class=\"r\">3,226<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">96<\/td><td class=\"k\">nmibc<\/td><td class=\"r\">2,285<\/td><td class=\"r\">2,416<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">97<\/td><td class=\"k\">acute ischemic stroke patients<\/td><td class=\"r\">2,766<\/td><td class=\"r\">2,914<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">98<\/td><td class=\"k\">diabetes medication<\/td><td class=\"r\">2,084<\/td><td class=\"r\">2,202<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">99<\/td><td class=\"k\">hiv-rna<\/td><td class=\"r\">1,457<\/td><td class=\"r\">1,509<\/td><td class=\"r\">18.99<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">100<\/td><td class=\"k\">anthracycline-based<\/td><td class=\"r\">2,096<\/td><td class=\"r\">2,215<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">101<\/td><td class=\"k\">a(h1n1)pdm09<\/td><td class=\"r\">1,391<\/td><td class=\"r\">1,434<\/td><td class=\"r\">18.99<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">102<\/td><td class=\"k\">follicular lymphoma (fl)<\/td><td class=\"r\">2,162<\/td><td class=\"r\">2,286<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">103<\/td><td class=\"k\">neoadjuvant chemotherapy (nac)<\/td><td class=\"r\">3,008<\/td><td class=\"r\">3,158<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">104<\/td><td class=\"k\">anaplastic lymphoma kinase (alk)<\/td><td class=\"r\">3,238<\/td><td class=\"r\">3,385<\/td><td class=\"r\">18.99<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">105<\/td><td class=\"k\">crc risk<\/td><td class=\"r\">2,166<\/td><td class=\"r\">2,291<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">106<\/td><td class=\"k\">interferon and ribavirin<\/td><td class=\"r\">2,755<\/td><td class=\"r\">2,905<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">107<\/td><td class=\"k\">trail-induced apoptosis<\/td><td class=\"r\">1,770<\/td><td class=\"r\">1,861<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">108<\/td><td class=\"k\">cancer stem-like cells<\/td><td class=\"r\">1,889<\/td><td class=\"r\">1,992<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">109<\/td><td class=\"k\">tuberculin skin test (tst)<\/td><td class=\"r\">1,797<\/td><td class=\"r\">1,891<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">110<\/td><td class=\"k\">cancer stem-like<\/td><td class=\"r\">2,353<\/td><td class=\"r\">2,490<\/td><td class=\"r\">18.99<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">111<\/td><td class=\"k\">cancer stem-like cell<\/td><td class=\"r\">2,098<\/td><td class=\"r\">2,219<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">112<\/td><td class=\"k\">clear cell rcc<\/td><td class=\"r\">1,758<\/td><td class=\"r\">1,848<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">113<\/td><td class=\"k\">childhood cancer survivors<\/td><td class=\"r\">2,471<\/td><td class=\"r\">2,614<\/td><td class=\"r\">18.99<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">114<\/td><td class=\"k\">exposure to pm2.5<\/td><td class=\"r\">2,051<\/td><td class=\"r\">2,169<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">115<\/td><td class=\"k\">egfr tk<\/td><td class=\"r\">1,758<\/td><td class=\"r\">1,849<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">116<\/td><td class=\"k\">asthma phenotype<\/td><td class=\"r\">1,709<\/td><td class=\"r\">1,795<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">117<\/td><td class=\"k\">slnb<\/td><td class=\"r\">2,728<\/td><td class=\"r\">2,881<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">118<\/td><td class=\"k\">marginal zone lymphoma<\/td><td class=\"r\">2,415<\/td><td class=\"r\">2,558<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">119<\/td><td class=\"k\">msi-h<\/td><td class=\"r\">2,347<\/td><td class=\"r\">2,487<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">120<\/td><td class=\"k\">pediatric obesity<\/td><td class=\"r\">2,384<\/td><td class=\"r\">2,526<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">121<\/td><td class=\"k\">mantle cell lymphoma (mcl)<\/td><td class=\"r\">2,344<\/td><td class=\"r\">2,484<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">122<\/td><td class=\"k\">differentiated thyroid cancer (dtc)<\/td><td class=\"r\">1,690<\/td><td class=\"r\">1,775<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">123<\/td><td class=\"k\">risk of ischemic stroke<\/td><td class=\"r\">2,533<\/td><td class=\"r\">2,682<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">124<\/td><td class=\"k\">sustained virologic response (svr)<\/td><td class=\"r\">1,491<\/td><td class=\"r\">1,552<\/td><td class=\"r\">18.98<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">125<\/td><td class=\"k\">metastatic nsclc<\/td><td class=\"r\">1,908<\/td><td class=\"r\">2,017<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">126<\/td><td class=\"k\">concurrent chemoradiation<\/td><td class=\"r\">2,105<\/td><td class=\"r\">2,231<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">127<\/td><td class=\"k\">egfr tki<\/td><td class=\"r\">1,645<\/td><td class=\"r\">1,726<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">128<\/td><td class=\"k\">shiga toxin-producing escherichia coli (stec)<\/td><td class=\"r\">1,619<\/td><td class=\"r\">1,697<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">129<\/td><td class=\"k\">stroke outcomes<\/td><td class=\"r\">1,640<\/td><td class=\"r\">1,721<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">130<\/td><td class=\"k\">and end results database<\/td><td class=\"r\">2,312<\/td><td class=\"r\">2,453<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">131<\/td><td class=\"k\">ca-mrsa<\/td><td class=\"r\">1,850<\/td><td class=\"r\">1,955<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">132<\/td><td class=\"k\">sustained virologic response<\/td><td class=\"r\">3,706<\/td><td class=\"r\">3,845<\/td><td class=\"r\">18.98<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">133<\/td><td class=\"k\">metastatic castration-resistant prostate cancer<\/td><td class=\"r\">3,249<\/td><td class=\"r\">3,407<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">134<\/td><td class=\"k\">health services access<\/td><td class=\"r\">2,126<\/td><td class=\"r\">2,256<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">135<\/td><td class=\"k\">asthma outcomes<\/td><td class=\"r\">1,317<\/td><td class=\"r\">1,355<\/td><td class=\"r\">18.98<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">136<\/td><td class=\"k\">latent tuberculosis infection (ltbi)<\/td><td class=\"r\">1,535<\/td><td class=\"r\">1,604<\/td><td class=\"r\">18.98<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">137<\/td><td class=\"k\">pharyngeal squamous cell carcinoma<\/td><td class=\"r\">3,342<\/td><td class=\"r\">3,499<\/td><td class=\"r\">18.98<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">138<\/td><td class=\"k\">hiv-infected adults<\/td><td class=\"r\">2,734<\/td><td class=\"r\">2,894<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">139<\/td><td class=\"k\">ckd stages<\/td><td class=\"r\">2,179<\/td><td class=\"r\">2,314<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">140<\/td><td class=\"k\">egfr-tkis<\/td><td class=\"r\">2,454<\/td><td class=\"r\">2,605<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">141<\/td><td class=\"k\">surveillance, epidemiology, and end results database<\/td><td class=\"r\">1,747<\/td><td class=\"r\">1,843<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">142<\/td><td class=\"k\">cvd events<\/td><td class=\"r\">3,143<\/td><td class=\"r\">3,306<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">143<\/td><td class=\"k\">hcv therapy<\/td><td class=\"r\">1,373<\/td><td class=\"r\">1,421<\/td><td class=\"r\">18.98<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">144<\/td><td class=\"k\">end results database<\/td><td class=\"r\">2,338<\/td><td class=\"r\">2,485<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">145<\/td><td class=\"k\">breast cancer mcf-7<\/td><td class=\"r\">2,195<\/td><td class=\"r\">2,333<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">146<\/td><td class=\"k\">national cancer data base<\/td><td class=\"r\">1,266<\/td><td class=\"r\">1,298<\/td><td class=\"r\">18.98<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">147<\/td><td class=\"k\">direct-acting antivirals<\/td><td class=\"r\">3,189<\/td><td class=\"r\">3,353<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">148<\/td><td class=\"k\">national comprehensive cancer network<\/td><td class=\"r\">3,878<\/td><td class=\"r\">4,013<\/td><td class=\"r\">18.98<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">149<\/td><td class=\"k\">chronic thromboembolic pulmonary hypertension (cteph)<\/td><td class=\"r\">1,540<\/td><td class=\"r\">1,612<\/td><td class=\"r\">18.98<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">150<\/td><td class=\"k\">milan criteria<\/td><td class=\"r\">1,609<\/td><td class=\"r\">1,690<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">151<\/td><td class=\"k\">crc screening<\/td><td class=\"r\">3,214<\/td><td class=\"r\">3,378<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">152<\/td><td class=\"k\">l858r<\/td><td class=\"r\">2,307<\/td><td class=\"r\">2,453<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">153<\/td><td class=\"k\">prostate cancer diagnosis<\/td><td class=\"r\">1,881<\/td><td class=\"r\">1,993<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">154<\/td><td class=\"k\">hiv\/sti<\/td><td class=\"r\">1,494<\/td><td class=\"r\">1,560<\/td><td class=\"r\">18.98<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">155<\/td><td class=\"k\">chb patients<\/td><td class=\"r\">2,869<\/td><td class=\"r\">3,035<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">156<\/td><td class=\"k\">anticancer efficacy<\/td><td class=\"r\">3,155<\/td><td class=\"r\">3,321<\/td><td class=\"r\">18.98<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">157<\/td><td class=\"k\">childhood cancer survivor<\/td><td class=\"r\">2,764<\/td><td class=\"r\">2,929<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">158<\/td><td class=\"k\">hiv acquisition<\/td><td class=\"r\">2,348<\/td><td class=\"r\">2,498<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">159<\/td><td class=\"k\">prevention of mother-to-child transmission<\/td><td class=\"r\">1,977<\/td><td class=\"r\">2,100<\/td><td class=\"r\">18.98<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">160<\/td><td class=\"k\">children with type 1 diabetes<\/td><td class=\"r\">2,625<\/td><td class=\"r\">2,788<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">161<\/td><td class=\"k\">significant prostate cancer<\/td><td class=\"r\">1,668<\/td><td class=\"r\">1,758<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">162<\/td><td class=\"k\">cancer targeted<\/td><td class=\"r\">2,467<\/td><td class=\"r\">2,624<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">163<\/td><td class=\"k\">latent tuberculosis infection<\/td><td class=\"r\">3,184<\/td><td class=\"r\">3,352<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">164<\/td><td class=\"k\">hiv prevention intervention<\/td><td class=\"r\">1,802<\/td><td class=\"r\">1,908<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">165<\/td><td class=\"k\">kaposi&#8217;s sarcoma-associated herpesvirus (kshv)<\/td><td class=\"r\">1,323<\/td><td class=\"r\">1,366<\/td><td class=\"r\">18.97<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">166<\/td><td class=\"k\">locally advanced rectal cancer<\/td><td class=\"r\">3,462<\/td><td class=\"r\">3,624<\/td><td class=\"r\">18.97<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">167<\/td><td class=\"k\">genotype 1b<\/td><td class=\"r\">2,162<\/td><td class=\"r\">2,302<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">168<\/td><td class=\"k\">stroke registry<\/td><td class=\"r\">2,004<\/td><td class=\"r\">2,131<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">169<\/td><td class=\"k\">sentinel nodes<\/td><td class=\"r\">2,037<\/td><td class=\"r\">2,167<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">170<\/td><td class=\"k\">peritoneal cancer<\/td><td class=\"r\">2,010<\/td><td class=\"r\">2,138<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">171<\/td><td class=\"k\">metastatic castration-resistant<\/td><td class=\"r\">3,419<\/td><td class=\"r\">3,584<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">172<\/td><td class=\"k\">escherichia coli (stec)<\/td><td class=\"r\">2,331<\/td><td class=\"r\">2,483<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">173<\/td><td class=\"k\">her2 expression<\/td><td class=\"r\">2,066<\/td><td class=\"r\">2,199<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">174<\/td><td class=\"k\">transarterial chemoembolization (tace)<\/td><td class=\"r\">2,411<\/td><td class=\"r\">2,568<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">175<\/td><td class=\"k\">hiv-exposed<\/td><td class=\"r\">1,766<\/td><td class=\"r\">1,870<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">176<\/td><td class=\"k\">improving global outcomes<\/td><td class=\"r\">2,092<\/td><td class=\"r\">2,228<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">177<\/td><td class=\"k\">hiv-1 subtypes<\/td><td class=\"r\">1,406<\/td><td class=\"r\">1,463<\/td><td class=\"r\">18.97<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">178<\/td><td class=\"k\">lymph node ratio<\/td><td class=\"r\">1,546<\/td><td class=\"r\">1,623<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">179<\/td><td class=\"k\">asthma diagnosis<\/td><td class=\"r\">1,744<\/td><td class=\"r\">1,846<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">180<\/td><td class=\"k\">castration-resistant prostate cancer (crpc)<\/td><td class=\"r\">2,451<\/td><td class=\"r\">2,612<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">181<\/td><td class=\"k\">hiv-1 integrase<\/td><td class=\"r\">1,825<\/td><td class=\"r\">1,937<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">182<\/td><td class=\"k\">brca1\/2 mutation<\/td><td class=\"r\">2,130<\/td><td class=\"r\">2,271<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">183<\/td><td class=\"k\">end-stage kidney disease (eskd)<\/td><td class=\"r\">1,566<\/td><td class=\"r\">1,647<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">184<\/td><td class=\"k\">obstructive cad<\/td><td class=\"r\">1,536<\/td><td class=\"r\">1,613<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">185<\/td><td class=\"k\">prostate cancer (pc)<\/td><td class=\"r\">3,303<\/td><td class=\"r\">3,477<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">186<\/td><td class=\"k\">b-cell lymphoma-2<\/td><td class=\"r\">1,677<\/td><td class=\"r\">1,773<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">187<\/td><td class=\"k\">folfiri<\/td><td class=\"r\">2,956<\/td><td class=\"r\">3,134<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">188<\/td><td class=\"k\">diabetic kidney disease (dkd)<\/td><td class=\"r\">1,993<\/td><td class=\"r\">2,124<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">189<\/td><td class=\"k\">mucosa-associated lymphoid tissue lymphoma<\/td><td class=\"r\">1,571<\/td><td class=\"r\">1,654<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">190<\/td><td class=\"k\">cancer pain relief<\/td><td class=\"r\">2,164<\/td><td class=\"r\">2,310<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">191<\/td><td class=\"k\">chronic hepatitis c patients<\/td><td class=\"r\">2,257<\/td><td class=\"r\">2,410<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">192<\/td><td class=\"k\">colorectal cancer risk<\/td><td class=\"r\">2,801<\/td><td class=\"r\">2,978<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">193<\/td><td class=\"k\">combination antiretroviral therapy (cart)<\/td><td class=\"r\">1,810<\/td><td class=\"r\">1,923<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">194<\/td><td class=\"k\">human prostate cancer cells<\/td><td class=\"r\">2,923<\/td><td class=\"r\">3,102<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">195<\/td><td class=\"k\">pathological complete response (pcr)<\/td><td class=\"r\">1,893<\/td><td class=\"r\">2,015<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">196<\/td><td class=\"k\">tki treatment<\/td><td class=\"r\">1,674<\/td><td class=\"r\">1,771<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">197<\/td><td class=\"k\">ln metastasis<\/td><td class=\"r\">2,703<\/td><td class=\"r\">2,878<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">198<\/td><td class=\"k\">pm2.5 exposure<\/td><td class=\"r\">2,904<\/td><td class=\"r\">3,083<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">199<\/td><td class=\"k\">incident stroke<\/td><td class=\"r\">1,358<\/td><td class=\"r\">1,411<\/td><td class=\"r\">18.97<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">200<\/td><td class=\"k\">cryptogenic stroke<\/td><td class=\"r\">1,880<\/td><td class=\"r\">2,001<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">201<\/td><td class=\"k\">recurrent ovarian cancer<\/td><td class=\"r\">2,011<\/td><td class=\"r\">2,145<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">202<\/td><td class=\"k\">crc cell lines<\/td><td class=\"r\">2,461<\/td><td class=\"r\">2,627<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">203<\/td><td class=\"k\">sentinel lymph node (sln)<\/td><td class=\"r\">3,107<\/td><td class=\"r\">3,287<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">204<\/td><td class=\"k\">sustained viral response<\/td><td class=\"r\">1,389<\/td><td class=\"r\">1,447<\/td><td class=\"r\">18.97<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">205<\/td><td class=\"k\">hodgkin lymphoma (hl)<\/td><td class=\"r\">2,301<\/td><td class=\"r\">2,458<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">206<\/td><td class=\"k\">adjuvant chemoradiation<\/td><td class=\"r\">2,842<\/td><td class=\"r\">3,021<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">207<\/td><td class=\"k\">tki therapy<\/td><td class=\"r\">1,607<\/td><td class=\"r\">1,696<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">208<\/td><td class=\"k\">hormone receptor-positive<\/td><td class=\"r\">3,088<\/td><td class=\"r\">3,269<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">209<\/td><td class=\"k\">hbv dna levels<\/td><td class=\"r\">1,691<\/td><td class=\"r\">1,791<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">210<\/td><td class=\"k\">breast cancer mcf-7 cell<\/td><td class=\"r\">1,649<\/td><td class=\"r\">1,744<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">211<\/td><td class=\"k\">new-onset diabetes<\/td><td class=\"r\">2,030<\/td><td class=\"r\">2,167<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">212<\/td><td class=\"k\">incidence of type 2 diabetes<\/td><td class=\"r\">1,719<\/td><td class=\"r\">1,823<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">213<\/td><td class=\"k\">anti-obesity effect<\/td><td class=\"r\">2,097<\/td><td class=\"r\">2,240<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">214<\/td><td class=\"k\">nonsmall cell lung cancer (nsclc)<\/td><td class=\"r\">1,464<\/td><td class=\"r\">1,534<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">215<\/td><td class=\"k\">peg-ifn<\/td><td class=\"r\">2,605<\/td><td class=\"r\">2,779<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">216<\/td><td class=\"k\">chronic hepatitis c virus (hcv)<\/td><td class=\"r\">3,381<\/td><td class=\"r\">3,559<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">217<\/td><td class=\"k\">p[8]<\/td><td class=\"r\">1,249<\/td><td class=\"r\">1,286<\/td><td class=\"r\">18.97<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">218<\/td><td class=\"k\">programmed death-ligand 1 (pd-l1)<\/td><td class=\"r\">2,057<\/td><td class=\"r\">2,197<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">219<\/td><td class=\"k\">chronic thromboembolic pulmonary hypertension<\/td><td class=\"r\">2,518<\/td><td class=\"r\">2,689<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">220<\/td><td class=\"k\">metastatic rcc<\/td><td class=\"r\">2,175<\/td><td class=\"r\">2,325<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">221<\/td><td class=\"k\">urothelial carcinoma (uc)<\/td><td class=\"r\">1,285<\/td><td class=\"r\">1,328<\/td><td class=\"r\">18.97<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">222<\/td><td class=\"k\">human colorectal cancer cell<\/td><td class=\"r\">2,214<\/td><td class=\"r\">2,367<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">223<\/td><td class=\"k\">resistant breast cancer<\/td><td class=\"r\">2,186<\/td><td class=\"r\">2,337<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">224<\/td><td class=\"k\">cancer-related genes<\/td><td class=\"r\">2,525<\/td><td class=\"r\">2,697<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">225<\/td><td class=\"k\">h5n1 virus<\/td><td class=\"r\">2,317<\/td><td class=\"r\">2,478<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">226<\/td><td class=\"k\">hiv coinfection<\/td><td class=\"r\">1,591<\/td><td class=\"r\">1,680<\/td><td class=\"r\">18.97<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">227<\/td><td class=\"k\">gastric cancer cell lines<\/td><td class=\"r\">2,653<\/td><td class=\"r\">2,831<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">228<\/td><td class=\"k\">thrombolysis in cerebral infarction<\/td><td class=\"r\">1,219<\/td><td class=\"r\">1,252<\/td><td class=\"r\">18.97<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">229<\/td><td class=\"k\">atherosclerotic cardiovascular disease (ascvd)<\/td><td class=\"r\">1,976<\/td><td class=\"r\">2,110<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">230<\/td><td class=\"k\">androgen deprivation therapy (adt)<\/td><td class=\"r\">2,986<\/td><td class=\"r\">3,171<\/td><td class=\"r\">18.97<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">231<\/td><td class=\"k\">flt3-itd<\/td><td class=\"r\">1,866<\/td><td class=\"r\">1,989<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">232<\/td><td class=\"k\">type 2 diabetes mellitus (dm)<\/td><td class=\"r\">2,632<\/td><td class=\"r\">2,810<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">233<\/td><td class=\"k\">virologic failure<\/td><td class=\"r\">1,639<\/td><td class=\"r\">1,735<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">234<\/td><td class=\"k\">cancer xenograft model<\/td><td class=\"r\">1,392<\/td><td class=\"r\">1,453<\/td><td class=\"r\">18.96<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">235<\/td><td class=\"k\">apoptosis of cancer cells<\/td><td class=\"r\">1,425<\/td><td class=\"r\">1,491<\/td><td class=\"r\">18.96<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">236<\/td><td class=\"k\">2009 h1n1<\/td><td class=\"r\">1,773<\/td><td class=\"r\">1,886<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">237<\/td><td class=\"k\">substance use disorder (sud)<\/td><td class=\"r\">2,249<\/td><td class=\"r\">2,407<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">238<\/td><td class=\"k\">asthma model<\/td><td class=\"r\">2,038<\/td><td class=\"r\">2,179<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">239<\/td><td class=\"k\">large vessel occlusion<\/td><td class=\"r\">2,921<\/td><td class=\"r\">3,107<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">240<\/td><td class=\"k\">anti-cancer properties<\/td><td class=\"r\">2,069<\/td><td class=\"r\">2,213<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">241<\/td><td class=\"k\">brca2 mutation<\/td><td class=\"r\">2,996<\/td><td class=\"r\">3,183<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">242<\/td><td class=\"k\">advanced non-small-cell lung cancer (nsclc)<\/td><td class=\"r\">1,565<\/td><td class=\"r\">1,652<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">243<\/td><td class=\"k\">hnscc patients<\/td><td class=\"r\">2,443<\/td><td class=\"r\">2,614<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">244<\/td><td class=\"k\">progression of chronic kidney disease<\/td><td class=\"r\">1,801<\/td><td class=\"r\">1,918<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">245<\/td><td class=\"k\">integrase inhibitor<\/td><td class=\"r\">2,420<\/td><td class=\"r\">2,590<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">246<\/td><td class=\"k\">chronic thromboembolic pulmonary<\/td><td class=\"r\">2,537<\/td><td class=\"r\">2,713<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">247<\/td><td class=\"k\">plasma hiv rna<\/td><td class=\"r\">1,278<\/td><td class=\"r\">1,322<\/td><td class=\"r\">18.96<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">248<\/td><td class=\"k\">her2-positive breast cancer<\/td><td class=\"r\">2,898<\/td><td class=\"r\">3,085<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">249<\/td><td class=\"k\">sentinel node biopsy<\/td><td class=\"r\">3,250<\/td><td class=\"r\">3,437<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">250<\/td><td class=\"k\">stroke subtypes<\/td><td class=\"r\">1,895<\/td><td class=\"r\">2,023<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">251<\/td><td class=\"k\">her2-negative<\/td><td class=\"r\">3,168<\/td><td class=\"r\">3,356<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">252<\/td><td class=\"k\">endometrial cancer (ec)<\/td><td class=\"r\">2,464<\/td><td class=\"r\">2,637<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">253<\/td><td class=\"k\">ln metastases<\/td><td class=\"r\">1,496<\/td><td class=\"r\">1,574<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">254<\/td><td class=\"k\">head-and-neck cancer<\/td><td class=\"r\">1,325<\/td><td class=\"r\">1,377<\/td><td class=\"r\">18.96<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">255<\/td><td class=\"k\">diabetes-related complication<\/td><td class=\"r\">1,703<\/td><td class=\"r\">1,809<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">256<\/td><td class=\"k\">stroke recurrence<\/td><td class=\"r\">2,144<\/td><td class=\"r\">2,296<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">257<\/td><td class=\"k\">her2 positive<\/td><td class=\"r\">1,826<\/td><td class=\"r\">1,947<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">258<\/td><td class=\"k\">diabetes self-management<\/td><td class=\"r\">3,170<\/td><td class=\"r\">3,359<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">259<\/td><td class=\"k\">muscle invasive bladder cancer<\/td><td class=\"r\">2,676<\/td><td class=\"r\">2,859<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">260<\/td><td class=\"k\">hepatitis c virus genotype<\/td><td class=\"r\">1,897<\/td><td class=\"r\">2,026<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">261<\/td><td class=\"k\">t790m<\/td><td class=\"r\">2,812<\/td><td class=\"r\">2,999<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">262<\/td><td class=\"k\">human neuroblastoma sh-sy5y<\/td><td class=\"r\">1,512<\/td><td class=\"r\">1,593<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">263<\/td><td class=\"k\">cancer cell survival<\/td><td class=\"r\">2,654<\/td><td class=\"r\">2,837<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">264<\/td><td class=\"k\">cancer-specific survival (css)<\/td><td class=\"r\">3,176<\/td><td class=\"r\">3,366<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">265<\/td><td class=\"k\">targeted cancer therapy<\/td><td class=\"r\">2,119<\/td><td class=\"r\">2,270<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">266<\/td><td class=\"k\">anticancer drug delivery<\/td><td class=\"r\">1,663<\/td><td class=\"r\">1,765<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">267<\/td><td class=\"k\">brca1 mutation<\/td><td class=\"r\">2,154<\/td><td class=\"r\">2,308<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">268<\/td><td class=\"k\">antiretroviral treatment (art)<\/td><td class=\"r\">2,175<\/td><td class=\"r\">2,331<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">269<\/td><td class=\"k\">women living with hiv<\/td><td class=\"r\">2,369<\/td><td class=\"r\">2,539<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">270<\/td><td class=\"k\">obesity status<\/td><td class=\"r\">1,771<\/td><td class=\"r\">1,887<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">271<\/td><td class=\"k\">h5n1 influenza<\/td><td class=\"r\">1,489<\/td><td class=\"r\">1,568<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">272<\/td><td class=\"k\">biochemical recurrence (bcr)<\/td><td class=\"r\">1,388<\/td><td class=\"r\">1,452<\/td><td class=\"r\">18.96<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">273<\/td><td class=\"k\">non-small cell lung cancer cells<\/td><td class=\"r\">2,050<\/td><td class=\"r\">2,197<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">274<\/td><td class=\"k\">alk-positive<\/td><td class=\"r\">1,679<\/td><td class=\"r\">1,785<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">275<\/td><td class=\"k\">co-infected patients<\/td><td class=\"r\">1,905<\/td><td class=\"r\">2,038<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">276<\/td><td class=\"k\">upper tract urothelial carcinoma<\/td><td class=\"r\">1,462<\/td><td class=\"r\">1,538<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">277<\/td><td class=\"k\">international study of asthma and allergies in childhood<\/td><td class=\"r\">1,132<\/td><td class=\"r\">1,154<\/td><td class=\"r\">18.96<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">278<\/td><td class=\"k\">metabolic tumor volume<\/td><td class=\"r\">1,558<\/td><td class=\"r\">1,648<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">279<\/td><td class=\"k\">cancer detection rate<\/td><td class=\"r\">2,179<\/td><td class=\"r\">2,338<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">280<\/td><td class=\"k\">diabetes-related complications<\/td><td class=\"r\">1,630<\/td><td class=\"r\">1,730<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">281<\/td><td class=\"k\">american joint committee on cancer (ajcc)<\/td><td class=\"r\">2,107<\/td><td class=\"r\">2,260<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">282<\/td><td class=\"k\">her2 overexpression<\/td><td class=\"r\">1,421<\/td><td class=\"r\">1,491<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">283<\/td><td class=\"k\">diabetes model<\/td><td class=\"r\">1,762<\/td><td class=\"r\">1,879<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">284<\/td><td class=\"k\">nucleos(t)ide analog<\/td><td class=\"r\">1,786<\/td><td class=\"r\">1,906<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">285<\/td><td class=\"k\">transcatheter arterial chemoembolization (tace)<\/td><td class=\"r\">1,873<\/td><td class=\"r\">2,003<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">286<\/td><td class=\"k\">cancer inflammation<\/td><td class=\"r\">1,728<\/td><td class=\"r\">1,841<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">287<\/td><td class=\"k\">pathologic complete response<\/td><td class=\"r\">3,332<\/td><td class=\"r\">3,525<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">288<\/td><td class=\"k\">hcc treatment<\/td><td class=\"r\">1,964<\/td><td class=\"r\">2,104<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">289<\/td><td class=\"k\">multidrug-resistant tuberculosis (mdr-tb)<\/td><td class=\"r\">1,478<\/td><td class=\"r\">1,557<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">290<\/td><td class=\"k\">obesity type<\/td><td class=\"r\">2,300<\/td><td class=\"r\">2,469<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">291<\/td><td class=\"k\">prostate cancer treatment<\/td><td class=\"r\">2,941<\/td><td class=\"r\">3,136<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">292<\/td><td class=\"k\">non-muscle-invasive bladder cancer<\/td><td class=\"r\">1,392<\/td><td class=\"r\">1,458<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">293<\/td><td class=\"k\">b-cell non-hodgkin lymphoma<\/td><td class=\"r\">1,538<\/td><td class=\"r\">1,626<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">294<\/td><td class=\"k\">xenograft tumor growth<\/td><td class=\"r\">1,509<\/td><td class=\"r\">1,593<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">295<\/td><td class=\"k\">chronic hepatitis b patients<\/td><td class=\"r\">2,592<\/td><td class=\"r\">2,778<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">296<\/td><td class=\"k\">visceral obesity<\/td><td class=\"r\">2,687<\/td><td class=\"r\">2,877<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">297<\/td><td class=\"k\">people living with hiv (plwh)<\/td><td class=\"r\">2,171<\/td><td class=\"r\">2,331<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">298<\/td><td class=\"k\">suicide gene<\/td><td class=\"r\">2,460<\/td><td class=\"r\">2,640<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">299<\/td><td class=\"k\">hcc development<\/td><td class=\"r\">2,912<\/td><td class=\"r\">3,108<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">300<\/td><td class=\"k\">breast cancer model<\/td><td class=\"r\">2,595<\/td><td class=\"r\">2,782<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">301<\/td><td class=\"k\">treatment of hepatitis c<\/td><td class=\"r\">2,050<\/td><td class=\"r\">2,200<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">302<\/td><td class=\"k\">egfr tyrosine kinase inhibitor<\/td><td class=\"r\">3,094<\/td><td class=\"r\">3,292<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">303<\/td><td class=\"k\">hnscc cells<\/td><td class=\"r\">1,293<\/td><td class=\"r\">1,344<\/td><td class=\"r\">18.96<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">304<\/td><td class=\"k\">eastern cooperative oncology group performance status<\/td><td class=\"r\">3,208<\/td><td class=\"r\">3,406<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">305<\/td><td class=\"k\">sh-sy5y neuroblastoma<\/td><td class=\"r\">1,886<\/td><td class=\"r\">2,020<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">306<\/td><td class=\"k\">cancer history<\/td><td class=\"r\">2,094<\/td><td class=\"r\">2,249<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">307<\/td><td class=\"k\">oscc cells<\/td><td class=\"r\">1,685<\/td><td class=\"r\">1,795<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">308<\/td><td class=\"k\">stroke subtype<\/td><td class=\"r\">2,970<\/td><td class=\"r\">3,169<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">309<\/td><td class=\"k\">brca mutation<\/td><td class=\"r\">2,700<\/td><td class=\"r\">2,893<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">310<\/td><td class=\"k\">resistant cancer cells<\/td><td class=\"r\">2,025<\/td><td class=\"r\">2,174<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">311<\/td><td class=\"k\">prostate-specific membrane<\/td><td class=\"r\">3,065<\/td><td class=\"r\">3,265<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">312<\/td><td class=\"k\">prostate-specific membrane antigen<\/td><td class=\"r\">3,050<\/td><td class=\"r\">3,250<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">313<\/td><td class=\"k\">breast cancer mcf-7 cells<\/td><td class=\"r\">1,391<\/td><td class=\"r\">1,459<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">314<\/td><td class=\"k\">svr12<\/td><td class=\"r\">1,268<\/td><td class=\"r\">1,316<\/td><td class=\"r\">18.96<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">315<\/td><td class=\"k\">brca2 mutations<\/td><td class=\"r\">1,679<\/td><td class=\"r\">1,789<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">316<\/td><td class=\"k\">tnbc cells<\/td><td class=\"r\">2,372<\/td><td class=\"r\">2,550<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">317<\/td><td class=\"k\">anticancer mechanism<\/td><td class=\"r\">1,554<\/td><td class=\"r\">1,647<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">318<\/td><td class=\"k\">nab-paclitaxel<\/td><td class=\"r\">1,919<\/td><td class=\"r\">2,058<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">319<\/td><td class=\"k\">overweight, obesity<\/td><td class=\"r\">1,779<\/td><td class=\"r\">1,902<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">320<\/td><td class=\"k\">hba 1c<\/td><td class=\"r\">2,144<\/td><td class=\"r\">2,305<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">321<\/td><td class=\"k\">metastatic setting<\/td><td class=\"r\">1,993<\/td><td class=\"r\">2,140<\/td><td class=\"r\">18.96<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">322<\/td><td class=\"k\">survivorship care<\/td><td class=\"r\">1,706<\/td><td class=\"r\">1,820<\/td><td class=\"r\">18.96<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">323<\/td><td class=\"k\">hiv rna level<\/td><td class=\"r\">1,253<\/td><td class=\"r\">1,299<\/td><td class=\"r\">18.96<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">324<\/td><td class=\"k\">cardiovascular disease (cvd) risk factors<\/td><td class=\"r\">1,405<\/td><td class=\"r\">1,476<\/td><td class=\"r\">18.96<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">325<\/td><td class=\"k\">allergy, asthma<\/td><td class=\"r\">4,618<\/td><td class=\"r\">4,736<\/td><td class=\"r\">18.95<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">326<\/td><td class=\"k\">anticancer therapeutic<\/td><td class=\"r\">2,791<\/td><td class=\"r\">2,989<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">327<\/td><td class=\"k\">ischemic stroke (is)<\/td><td class=\"r\">2,439<\/td><td class=\"r\">2,622<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">328<\/td><td class=\"k\">human neuroblastoma sh-sy5y cell<\/td><td class=\"r\">1,404<\/td><td class=\"r\">1,475<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">329<\/td><td class=\"k\">diabetes technology<\/td><td class=\"r\">1,695<\/td><td class=\"r\">1,808<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">330<\/td><td class=\"k\">nsclc cell lines<\/td><td class=\"r\">2,714<\/td><td class=\"r\">2,910<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">331<\/td><td class=\"k\">effusion lymphoma<\/td><td class=\"r\">1,474<\/td><td class=\"r\">1,556<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">332<\/td><td class=\"k\">chronic kidney disease epidemiology collaboration<\/td><td class=\"r\">1,268<\/td><td class=\"r\">1,317<\/td><td class=\"r\">18.95<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">333<\/td><td class=\"k\">lung cancer surgery<\/td><td class=\"r\">1,899<\/td><td class=\"r\">2,037<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">334<\/td><td class=\"k\">denv-2<\/td><td class=\"r\">1,453<\/td><td class=\"r\">1,532<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">335<\/td><td class=\"k\">incident cvd<\/td><td class=\"r\">1,279<\/td><td class=\"r\">1,330<\/td><td class=\"r\">18.95<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">336<\/td><td class=\"k\">cvd event<\/td><td class=\"r\">3,627<\/td><td class=\"r\">3,820<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">337<\/td><td class=\"k\">acute ischaemic stroke<\/td><td class=\"r\">2,405<\/td><td class=\"r\">2,587<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">338<\/td><td class=\"k\">prevalence of type 2 diabetes<\/td><td class=\"r\">2,454<\/td><td class=\"r\">2,639<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">339<\/td><td class=\"k\">cteph<\/td><td class=\"r\">1,784<\/td><td class=\"r\">1,909<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">340<\/td><td class=\"k\">oligometastatic<\/td><td class=\"r\">2,283<\/td><td class=\"r\">2,457<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">341<\/td><td class=\"k\">virological failure<\/td><td class=\"r\">2,123<\/td><td class=\"r\">2,284<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">342<\/td><td class=\"k\">breast cancer susceptibility<\/td><td class=\"r\">2,629<\/td><td class=\"r\">2,823<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">343<\/td><td class=\"k\">t790m mutation<\/td><td class=\"r\">1,418<\/td><td class=\"r\">1,492<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">344<\/td><td class=\"k\">glucagon-like peptide-1 receptor agonist<\/td><td class=\"r\">2,253<\/td><td class=\"r\">2,425<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">345<\/td><td class=\"k\">large b-cell lymphomas<\/td><td class=\"r\">1,514<\/td><td class=\"r\">1,603<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">346<\/td><td class=\"k\">hepatitis c treatment<\/td><td class=\"r\">1,329<\/td><td class=\"r\">1,389<\/td><td class=\"r\">18.95<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">347<\/td><td class=\"k\">pca cells<\/td><td class=\"r\">2,566<\/td><td class=\"r\">2,758<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">348<\/td><td class=\"k\">disease control rate (dcr)<\/td><td class=\"r\">2,115<\/td><td class=\"r\">2,276<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">349<\/td><td class=\"k\">second-line chemotherapy<\/td><td class=\"r\">2,613<\/td><td class=\"r\">2,808<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">350<\/td><td class=\"k\">linkage to care<\/td><td class=\"r\">1,635<\/td><td class=\"r\">1,742<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">351<\/td><td class=\"k\">a549 lung cancer cells<\/td><td class=\"r\">1,242<\/td><td class=\"r\">1,288<\/td><td class=\"r\">18.95<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">352<\/td><td class=\"k\">controlled asthma<\/td><td class=\"r\">3,334<\/td><td class=\"r\">3,539<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">353<\/td><td class=\"k\">prostate cancer progression<\/td><td class=\"r\">3,111<\/td><td class=\"r\">3,318<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">354<\/td><td class=\"k\">locally advanced cervical cancer<\/td><td class=\"r\">1,768<\/td><td class=\"r\">1,893<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">355<\/td><td class=\"k\">nucleos(t)ide<\/td><td class=\"r\">2,132<\/td><td class=\"r\">2,296<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">356<\/td><td class=\"k\">tumor necrosis factor-related apoptosis-inducing ligand (trail)<\/td><td class=\"r\">1,789<\/td><td class=\"r\">1,917<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">357<\/td><td class=\"k\">persistent asthma<\/td><td class=\"r\">3,700<\/td><td class=\"r\">3,895<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">358<\/td><td class=\"k\">symptomatic intracranial hemorrhage<\/td><td class=\"r\">1,578<\/td><td class=\"r\">1,678<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">359<\/td><td class=\"k\">men living with hiv<\/td><td class=\"r\">2,915<\/td><td class=\"r\">3,121<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">360<\/td><td class=\"k\">hiv stigma<\/td><td class=\"r\">1,418<\/td><td class=\"r\">1,494<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">361<\/td><td class=\"k\">concurrent chemoradiotherapy (ccrt)<\/td><td class=\"r\">1,360<\/td><td class=\"r\">1,427<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">362<\/td><td class=\"k\">advanced hcc<\/td><td class=\"r\">3,355<\/td><td class=\"r\">3,562<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">363<\/td><td class=\"k\">international diabetes federation<\/td><td class=\"r\">2,811<\/td><td class=\"r\">3,016<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">364<\/td><td class=\"k\">b-cell lymphoma 2<\/td><td class=\"r\">2,713<\/td><td class=\"r\">2,915<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">365<\/td><td class=\"k\">stroke therapy<\/td><td class=\"r\">2,228<\/td><td class=\"r\">2,402<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">366<\/td><td class=\"k\">pancreatic cancer cell lines<\/td><td class=\"r\">2,787<\/td><td class=\"r\">2,992<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">367<\/td><td class=\"k\">tumor necrosis factor-related apoptosis-inducing ligand<\/td><td class=\"r\">2,467<\/td><td class=\"r\">2,658<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">368<\/td><td class=\"k\">cancer-related gene<\/td><td class=\"r\">2,966<\/td><td class=\"r\">3,175<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">369<\/td><td class=\"k\">curative-intent<\/td><td class=\"r\">1,698<\/td><td class=\"r\">1,816<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">370<\/td><td class=\"k\">microvascular invasion<\/td><td class=\"r\">1,675<\/td><td class=\"r\">1,790<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">371<\/td><td class=\"k\">response to neoadjuvant chemotherapy<\/td><td class=\"r\">1,973<\/td><td class=\"r\">2,124<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">372<\/td><td class=\"k\">breast cancer resistance protein (bcrp)<\/td><td class=\"r\">1,186<\/td><td class=\"r\">1,224<\/td><td class=\"r\">18.95<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">373<\/td><td class=\"k\">cancer stem cell (csc)<\/td><td class=\"r\">1,891<\/td><td class=\"r\">2,033<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">374<\/td><td class=\"k\">carcinoma, hepatocellular<\/td><td class=\"r\">1,214<\/td><td class=\"r\">1,257<\/td><td class=\"r\">18.95<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">375<\/td><td class=\"k\">mpmri<\/td><td class=\"r\">1,873<\/td><td class=\"r\">2,013<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">376<\/td><td class=\"k\">nonsmall cell lung cancer<\/td><td class=\"r\">2,925<\/td><td class=\"r\">3,134<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">377<\/td><td class=\"k\">bladder cancer (bc)<\/td><td class=\"r\">1,934<\/td><td class=\"r\">2,081<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">378<\/td><td class=\"k\">diffuse large b cell lymphoma<\/td><td class=\"r\">3,232<\/td><td class=\"r\">3,443<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">379<\/td><td class=\"k\">ventilator-associated pneumonia (vap)<\/td><td class=\"r\">2,944<\/td><td class=\"r\">3,154<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">380<\/td><td class=\"k\">hormone-refractory<\/td><td class=\"r\">1,938<\/td><td class=\"r\">2,086<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">381<\/td><td class=\"k\">ckd progression<\/td><td class=\"r\">1,917<\/td><td class=\"r\">2,063<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">382<\/td><td class=\"k\">hepatocellular carcinoma (hcc) cells<\/td><td class=\"r\">1,356<\/td><td class=\"r\">1,424<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">383<\/td><td class=\"k\">gemcitabine (gem)<\/td><td class=\"r\">1,474<\/td><td class=\"r\">1,561<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">384<\/td><td class=\"k\">denv infection<\/td><td class=\"r\">1,600<\/td><td class=\"r\">1,706<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">385<\/td><td class=\"k\">cancer mechanism<\/td><td class=\"r\">2,792<\/td><td class=\"r\">3,000<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">386<\/td><td class=\"k\">atherosclerosis cardiovascular disease<\/td><td class=\"r\">2,690<\/td><td class=\"r\">2,895<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">387<\/td><td class=\"k\">persons living with hiv<\/td><td class=\"r\">2,263<\/td><td class=\"r\">2,443<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">388<\/td><td class=\"k\">hmlh1<\/td><td class=\"r\">1,728<\/td><td class=\"r\">1,852<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">389<\/td><td class=\"k\">ncdb<\/td><td class=\"r\">1,638<\/td><td class=\"r\">1,750<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">390<\/td><td class=\"k\">preoperative chemoradiotherapy<\/td><td class=\"r\">1,638<\/td><td class=\"r\">1,750<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">391<\/td><td class=\"k\">neoplasm staging<\/td><td class=\"r\">1,749<\/td><td class=\"r\">1,876<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">392<\/td><td class=\"k\">cancer cost<\/td><td class=\"r\">1,702<\/td><td class=\"r\">1,823<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">393<\/td><td class=\"k\">incident type 2 diabetes<\/td><td class=\"r\">1,166<\/td><td class=\"r\">1,202<\/td><td class=\"r\">18.95<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">394<\/td><td class=\"k\">testis antigen<\/td><td class=\"r\">1,636<\/td><td class=\"r\">1,748<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">395<\/td><td class=\"k\">b16f10 melanoma<\/td><td class=\"r\">1,826<\/td><td class=\"r\">1,963<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">396<\/td><td class=\"k\">seasonal influenza vaccine<\/td><td class=\"r\">1,552<\/td><td class=\"r\">1,652<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">397<\/td><td class=\"k\">prostate cancer detection<\/td><td class=\"r\">1,937<\/td><td class=\"r\">2,087<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">398<\/td><td class=\"k\">hiv co-infection<\/td><td class=\"r\">2,134<\/td><td class=\"r\">2,304<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">399<\/td><td class=\"k\">merkel cell carcinoma (mcc)<\/td><td class=\"r\">1,523<\/td><td class=\"r\">1,619<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">400<\/td><td class=\"k\">sh-sy5y neuroblastoma cell<\/td><td class=\"r\">1,751<\/td><td class=\"r\">1,879<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">401<\/td><td class=\"k\">brca1 or brca2<\/td><td class=\"r\">1,646<\/td><td class=\"r\">1,760<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">402<\/td><td class=\"k\">primary effusion lymphoma<\/td><td class=\"r\">1,432<\/td><td class=\"r\">1,514<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">403<\/td><td class=\"k\">esophageal cancer (ec)<\/td><td class=\"r\">1,688<\/td><td class=\"r\">1,808<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">404<\/td><td class=\"k\">human colorectal cancer cells<\/td><td class=\"r\">1,400<\/td><td class=\"r\">1,477<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">405<\/td><td class=\"k\">neoadjuvant chemoradiotherapy<\/td><td class=\"r\">3,352<\/td><td class=\"r\">3,567<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">406<\/td><td class=\"k\">cardiovascular disease (cvd) risk<\/td><td class=\"r\">3,968<\/td><td class=\"r\">4,160<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">407<\/td><td class=\"k\">epidermal growth factor receptor tyrosine kinase inhibitor<\/td><td class=\"r\">1,578<\/td><td class=\"r\">1,683<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">408<\/td><td class=\"k\">pmtct<\/td><td class=\"r\">2,047<\/td><td class=\"r\">2,210<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">409<\/td><td class=\"k\">lung cancer treatment<\/td><td class=\"r\">2,637<\/td><td class=\"r\">2,843<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">410<\/td><td class=\"k\">epidermal growth factor receptor-2<\/td><td class=\"r\">1,576<\/td><td class=\"r\">1,681<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">411<\/td><td class=\"k\">extrathyroidal extension<\/td><td class=\"r\">1,377<\/td><td class=\"r\">1,451<\/td><td class=\"r\">18.95<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">412<\/td><td class=\"k\">primary effusion<\/td><td class=\"r\">1,457<\/td><td class=\"r\">1,544<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">413<\/td><td class=\"k\">hiv-related stigma<\/td><td class=\"r\">1,230<\/td><td class=\"r\">1,279<\/td><td class=\"r\">18.95<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">414<\/td><td class=\"k\">human cervical cancer cell<\/td><td class=\"r\">1,768<\/td><td class=\"r\">1,900<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">415<\/td><td class=\"k\">lung cancer a549<\/td><td class=\"r\">1,442<\/td><td class=\"r\">1,527<\/td><td class=\"r\">18.95<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">416<\/td><td class=\"k\">art adherence<\/td><td class=\"r\">1,864<\/td><td class=\"r\">2,008<\/td><td class=\"r\">18.95<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">417<\/td><td class=\"k\">gleason scores<\/td><td class=\"r\">1,749<\/td><td class=\"r\">1,879<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">418<\/td><td class=\"k\">internal tandem duplication<\/td><td class=\"r\">1,497<\/td><td class=\"r\">1,591<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">419<\/td><td class=\"k\">epidermal growth factor receptor mutation<\/td><td class=\"r\">1,325<\/td><td class=\"r\">1,391<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">420<\/td><td class=\"k\">influenza a(h1n1)<\/td><td class=\"r\">1,665<\/td><td class=\"r\">1,784<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">421<\/td><td class=\"k\">cancer theranostic<\/td><td class=\"r\">2,018<\/td><td class=\"r\">2,180<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">422<\/td><td class=\"k\">recurrent prostate cancer<\/td><td class=\"r\">1,461<\/td><td class=\"r\">1,550<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">423<\/td><td class=\"k\">classical hodgkin lymphoma<\/td><td class=\"r\">1,380<\/td><td class=\"r\">1,456<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">424<\/td><td class=\"k\">autoimmune hepatitis (aih)<\/td><td class=\"r\">2,275<\/td><td class=\"r\">2,462<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">425<\/td><td class=\"k\">human epidermal growth factor receptor-2<\/td><td class=\"r\">1,527<\/td><td class=\"r\">1,627<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">426<\/td><td class=\"k\">advanced chronic kidney disease<\/td><td class=\"r\">1,462<\/td><td class=\"r\">1,552<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">427<\/td><td class=\"k\">time to progression (ttp)<\/td><td class=\"r\">1,655<\/td><td class=\"r\">1,774<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">428<\/td><td class=\"k\">cancer cell viability<\/td><td class=\"r\">1,441<\/td><td class=\"r\">1,528<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">429<\/td><td class=\"k\">alcohol use disorders identification test (audit)<\/td><td class=\"r\">1,164<\/td><td class=\"r\">1,203<\/td><td class=\"r\">18.94<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">430<\/td><td class=\"k\">highly pathogenic avian influenza virus<\/td><td class=\"r\">1,332<\/td><td class=\"r\">1,401<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">431<\/td><td class=\"k\">five-year overall survival<\/td><td class=\"r\">1,958<\/td><td class=\"r\">2,116<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">432<\/td><td class=\"k\">objective response rate (orr)<\/td><td class=\"r\">3,631<\/td><td class=\"r\">3,847<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">433<\/td><td class=\"k\">breast cancer subtypes<\/td><td class=\"r\">2,695<\/td><td class=\"r\">2,909<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">434<\/td><td class=\"k\">epithelial ovarian cancer (eoc)<\/td><td class=\"r\">3,539<\/td><td class=\"r\">3,758<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">435<\/td><td class=\"k\">opioid use disorder (oud)<\/td><td class=\"r\">2,090<\/td><td class=\"r\">2,262<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">436<\/td><td class=\"k\">trastuzumab<\/td><td class=\"r\">2,293<\/td><td class=\"r\">2,483<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">437<\/td><td class=\"k\">abirateron<\/td><td class=\"r\">2,690<\/td><td class=\"r\">2,904<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">438<\/td><td class=\"k\">abiraterone<\/td><td class=\"r\">2,685<\/td><td class=\"r\">2,899<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">439<\/td><td class=\"k\">non-muscle invasive<\/td><td class=\"r\">1,795<\/td><td class=\"r\">1,934<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">440<\/td><td class=\"k\">total lesion glycolysis<\/td><td class=\"r\">1,375<\/td><td class=\"r\">1,452<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">441<\/td><td class=\"k\">5-year dfs<\/td><td class=\"r\">1,590<\/td><td class=\"r\">1,701<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">442<\/td><td class=\"k\">neoadjuvant chemotherapy (nact)<\/td><td class=\"r\">1,369<\/td><td class=\"r\">1,445<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">443<\/td><td class=\"k\">lifetime cancer risk<\/td><td class=\"r\">2,024<\/td><td class=\"r\">2,190<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">444<\/td><td class=\"k\">adults with diabetes<\/td><td class=\"r\">2,864<\/td><td class=\"r\">3,085<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">445<\/td><td class=\"k\">treatment-experienced<\/td><td class=\"r\">1,729<\/td><td class=\"r\">1,860<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">446<\/td><td class=\"k\">glucagon-like peptide-1 receptor agonists<\/td><td class=\"r\">1,439<\/td><td class=\"r\">1,527<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">447<\/td><td class=\"k\">alcohol use disorder (aud)<\/td><td class=\"r\">2,837<\/td><td class=\"r\">3,058<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">448<\/td><td class=\"k\">mucosa-associated lymphoid tissue (malt) lymphoma<\/td><td class=\"r\">1,426<\/td><td class=\"r\">1,512<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">449<\/td><td class=\"k\">diffuse large b cell<\/td><td class=\"r\">3,485<\/td><td class=\"r\">3,708<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">450<\/td><td class=\"k\">cancer mouse model<\/td><td class=\"r\">1,450<\/td><td class=\"r\">1,540<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">451<\/td><td class=\"k\">hcc progression<\/td><td class=\"r\">2,375<\/td><td class=\"r\">2,573<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">452<\/td><td class=\"k\">stroke centers<\/td><td class=\"r\">1,228<\/td><td class=\"r\">1,280<\/td><td class=\"r\">18.94<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">453<\/td><td class=\"k\">hiv viral load<\/td><td class=\"r\">3,440<\/td><td class=\"r\">3,665<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">454<\/td><td class=\"k\">obesity weight loss<\/td><td class=\"r\">1,602<\/td><td class=\"r\">1,716<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">455<\/td><td class=\"k\">receptor tyrosine kinase inhibitors<\/td><td class=\"r\">1,552<\/td><td class=\"r\">1,659<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">456<\/td><td class=\"k\">acute ischemic stroke (ais)<\/td><td class=\"r\">3,805<\/td><td class=\"r\">4,019<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">457<\/td><td class=\"k\">braf mutations<\/td><td class=\"r\">2,632<\/td><td class=\"r\">2,847<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">458<\/td><td class=\"k\">chronic thromboembolic<\/td><td class=\"r\">2,802<\/td><td class=\"r\">3,024<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">459<\/td><td class=\"k\">human hepatocellular carcinoma (hcc)<\/td><td class=\"r\">1,940<\/td><td class=\"r\">2,099<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">460<\/td><td class=\"k\">human prostate cancer cell line<\/td><td class=\"r\">1,839<\/td><td class=\"r\">1,986<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">461<\/td><td class=\"k\">programmed cell death ligand<\/td><td class=\"r\">1,939<\/td><td class=\"r\">2,098<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">462<\/td><td class=\"k\">advanced non-small-cell lung cancer<\/td><td class=\"r\">3,154<\/td><td class=\"r\">3,383<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">463<\/td><td class=\"k\">bxpc-3<\/td><td class=\"r\">1,643<\/td><td class=\"r\">1,764<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">464<\/td><td class=\"k\">neoadjuvant setting<\/td><td class=\"r\">1,690<\/td><td class=\"r\">1,818<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">465<\/td><td class=\"k\">melanoma differentiation<\/td><td class=\"r\">1,321<\/td><td class=\"r\">1,391<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">466<\/td><td class=\"k\">pi-rads<\/td><td class=\"r\">1,390<\/td><td class=\"r\">1,472<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">467<\/td><td class=\"k\">enzalutamid<\/td><td class=\"r\">2,566<\/td><td class=\"r\">2,780<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">468<\/td><td class=\"k\">microsatellite stable<\/td><td class=\"r\">1,323<\/td><td class=\"r\">1,394<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">469<\/td><td class=\"k\">enzalutamide<\/td><td class=\"r\">2,562<\/td><td class=\"r\">2,776<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">470<\/td><td class=\"k\">anti-cancer activities<\/td><td class=\"r\">1,770<\/td><td class=\"r\">1,910<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">471<\/td><td class=\"k\">colorectal cancer cell lines<\/td><td class=\"r\">2,010<\/td><td class=\"r\">2,179<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">472<\/td><td class=\"k\">spoligotyping<\/td><td class=\"r\">1,483<\/td><td class=\"r\">1,581<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">473<\/td><td class=\"k\">type 1 diabetes mellitus (t1dm)<\/td><td class=\"r\">4,036<\/td><td class=\"r\">4,242<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">474<\/td><td class=\"k\">tyrosine kinase inhibitor (tki)<\/td><td class=\"r\">3,011<\/td><td class=\"r\">3,242<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">475<\/td><td class=\"k\">upper tract urothelial<\/td><td class=\"r\">1,636<\/td><td class=\"r\">1,758<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">476<\/td><td class=\"k\">tongue squamous cell carcinoma<\/td><td class=\"r\">1,691<\/td><td class=\"r\">1,821<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">477<\/td><td class=\"k\">protumor<\/td><td class=\"r\">1,849<\/td><td class=\"r\">2,000<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">478<\/td><td class=\"k\">chronic hiv<\/td><td class=\"r\">1,705<\/td><td class=\"r\">1,837<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">479<\/td><td class=\"k\">human hepatocellular carcinoma cells<\/td><td class=\"r\">1,460<\/td><td class=\"r\">1,555<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">480<\/td><td class=\"k\">targeted anticancer<\/td><td class=\"r\">1,490<\/td><td class=\"r\">1,590<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">481<\/td><td class=\"k\">advanced non-small cell lung cancer (nsclc)<\/td><td class=\"r\">3,630<\/td><td class=\"r\">3,857<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">482<\/td><td class=\"k\">chronic hepatitis c virus infection<\/td><td class=\"r\">1,919<\/td><td class=\"r\">2,079<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">483<\/td><td class=\"k\">common toxicity criteria<\/td><td class=\"r\">1,507<\/td><td class=\"r\">1,610<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">484<\/td><td class=\"k\">diabetes prevention program<\/td><td class=\"r\">1,350<\/td><td class=\"r\">1,427<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">485<\/td><td class=\"k\">human hepatocellular carcinoma cell<\/td><td class=\"r\">2,520<\/td><td class=\"r\">2,734<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">486<\/td><td class=\"k\">stable coronary artery disease (cad)<\/td><td class=\"r\">1,151<\/td><td class=\"r\">1,192<\/td><td class=\"r\">18.94<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">487<\/td><td class=\"k\">obesity paradox<\/td><td class=\"r\">1,332<\/td><td class=\"r\">1,406<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">488<\/td><td class=\"k\">stroke units<\/td><td class=\"r\">1,518<\/td><td class=\"r\">1,623<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">489<\/td><td class=\"k\">h7n9<\/td><td class=\"r\">1,939<\/td><td class=\"r\">2,102<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">490<\/td><td class=\"k\">prostate cancer (cap)<\/td><td class=\"r\">1,177<\/td><td class=\"r\">1,223<\/td><td class=\"r\">18.94<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">491<\/td><td class=\"k\">prior stroke<\/td><td class=\"r\">1,575<\/td><td class=\"r\">1,689<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">492<\/td><td class=\"k\">pegylated interferon and ribavirin<\/td><td class=\"r\">1,198<\/td><td class=\"r\">1,248<\/td><td class=\"r\">18.94<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">493<\/td><td class=\"k\">stroke severity<\/td><td class=\"r\">4,244<\/td><td class=\"r\">4,440<\/td><td class=\"r\">18.94<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">494<\/td><td class=\"k\">cancer susceptibility gene<\/td><td class=\"r\">2,261<\/td><td class=\"r\">2,457<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">495<\/td><td class=\"k\">pediatric asthma<\/td><td class=\"r\">2,457<\/td><td class=\"r\">2,668<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">496<\/td><td class=\"k\">a(h1n1)<\/td><td class=\"r\">2,708<\/td><td class=\"r\">2,933<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">497<\/td><td class=\"k\">oral cancer cell<\/td><td class=\"r\">1,672<\/td><td class=\"r\">1,801<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">498<\/td><td class=\"k\">human neuroblastoma sh-sy5y cells<\/td><td class=\"r\">1,250<\/td><td class=\"r\">1,310<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">499<\/td><td class=\"k\">lymphovascular space<\/td><td class=\"r\">1,239<\/td><td class=\"r\">1,297<\/td><td class=\"r\">18.94<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">500<\/td><td class=\"k\">integrase inhibitors<\/td><td class=\"r\">1,532<\/td><td class=\"r\">1,640<\/td><td class=\"r\">18.94<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">501<\/td><td class=\"k\">cancer cell migration and invasion<\/td><td class=\"r\">1,427<\/td><td class=\"r\">1,518<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">502<\/td><td class=\"k\">insulin resistance obesity<\/td><td class=\"r\">2,747<\/td><td class=\"r\">2,974<\/td><td class=\"r\">18.94<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">503<\/td><td class=\"k\">clinical benefit rate<\/td><td class=\"r\">1,322<\/td><td class=\"r\">1,395<\/td><td class=\"r\">18.94<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">504<\/td><td class=\"k\">large b cell lymphoma<\/td><td class=\"r\">3,569<\/td><td class=\"r\">3,801<\/td><td class=\"r\">18.94<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">505<\/td><td class=\"k\">hepatitis c patients<\/td><td class=\"r\">3,285<\/td><td class=\"r\">3,522<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">506<\/td><td class=\"k\">sy5y neuroblastoma<\/td><td class=\"r\">2,004<\/td><td class=\"r\">2,176<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">507<\/td><td class=\"k\">hcv patients<\/td><td class=\"r\">3,353<\/td><td class=\"r\">3,590<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">508<\/td><td class=\"k\">uncomplicated malaria<\/td><td class=\"r\">1,924<\/td><td class=\"r\">2,087<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">509<\/td><td class=\"k\">antiretroviral regimen<\/td><td class=\"r\">2,221<\/td><td class=\"r\">2,415<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">510<\/td><td class=\"k\">hormone-refractory prostate cancer<\/td><td class=\"r\">1,274<\/td><td class=\"r\">1,339<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">511<\/td><td class=\"k\">cancer-associated fibroblasts (cafs)<\/td><td class=\"r\">2,114<\/td><td class=\"r\">2,298<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">512<\/td><td class=\"k\">xenograft tumor model<\/td><td class=\"r\">2,240<\/td><td class=\"r\">2,436<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">513<\/td><td class=\"k\">hepatitis c (hcv)<\/td><td class=\"r\">2,174<\/td><td class=\"r\">2,364<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">514<\/td><td class=\"k\">and type 1 diabetes<\/td><td class=\"r\">2,017<\/td><td class=\"r\">2,191<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">515<\/td><td class=\"k\">stage i nsclc<\/td><td class=\"r\">1,170<\/td><td class=\"r\">1,216<\/td><td class=\"r\">18.93<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">516<\/td><td class=\"k\">cervical cancer (cc)<\/td><td class=\"r\">2,016<\/td><td class=\"r\">2,190<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">517<\/td><td class=\"k\">hiv cohort<\/td><td class=\"r\">1,245<\/td><td class=\"r\">1,305<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">518<\/td><td class=\"k\">a\/h1n1<\/td><td class=\"r\">1,920<\/td><td class=\"r\">2,083<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">519<\/td><td class=\"k\">nodal staging<\/td><td class=\"r\">1,463<\/td><td class=\"r\">1,561<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">520<\/td><td class=\"k\">nk\/t-cell lymphoma<\/td><td class=\"r\">1,283<\/td><td class=\"r\">1,350<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">521<\/td><td class=\"k\">chronic thromboemboli<\/td><td class=\"r\">2,852<\/td><td class=\"r\">3,085<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">522<\/td><td class=\"k\">secondary stroke<\/td><td class=\"r\">1,510<\/td><td class=\"r\">1,616<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">523<\/td><td class=\"k\">treatment of chronic hepatitis c<\/td><td class=\"r\">2,065<\/td><td class=\"r\">2,245<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">524<\/td><td class=\"k\">cancer apoptosis<\/td><td class=\"r\">1,434<\/td><td class=\"r\">1,528<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">525<\/td><td class=\"k\">european organization for research and treatment of cancer<\/td><td class=\"r\">3,843<\/td><td class=\"r\">4,069<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">526<\/td><td class=\"k\">thromboembolic pulmonary hypertension<\/td><td class=\"r\">2,575<\/td><td class=\"r\">2,797<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">527<\/td><td class=\"k\">anti-obesity effects<\/td><td class=\"r\">1,329<\/td><td class=\"r\">1,405<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">528<\/td><td class=\"k\">multikinase inhibitor<\/td><td class=\"r\">1,754<\/td><td class=\"r\">1,897<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">529<\/td><td class=\"k\">response evaluation criteria in solid tumors<\/td><td class=\"r\">3,783<\/td><td class=\"r\">4,012<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">530<\/td><td class=\"k\">folfox<\/td><td class=\"r\">3,932<\/td><td class=\"r\">4,154<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">531<\/td><td class=\"k\">cancer drug delivery<\/td><td class=\"r\">3,371<\/td><td class=\"r\">3,611<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">532<\/td><td class=\"k\">asthma quality of life<\/td><td class=\"r\">1,197<\/td><td class=\"r\">1,249<\/td><td class=\"r\">18.93<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">533<\/td><td class=\"k\">diabetes diagnosis<\/td><td class=\"r\">2,381<\/td><td class=\"r\">2,591<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">534<\/td><td class=\"k\">chronic kidney disease patients<\/td><td class=\"r\">2,906<\/td><td class=\"r\">3,143<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">535<\/td><td class=\"k\">nk\/t-cell<\/td><td class=\"r\">1,343<\/td><td class=\"r\">1,422<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">536<\/td><td class=\"k\">cancer specific survival<\/td><td class=\"r\">1,478<\/td><td class=\"r\">1,580<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">537<\/td><td class=\"k\">cancer cell death<\/td><td class=\"r\">3,763<\/td><td class=\"r\">3,994<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">538<\/td><td class=\"k\">colorectal cancer cell line<\/td><td class=\"r\">3,022<\/td><td class=\"r\">3,262<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">539<\/td><td class=\"k\">hnscc cell lines<\/td><td class=\"r\">1,205<\/td><td class=\"r\">1,259<\/td><td class=\"r\">18.93<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">540<\/td><td class=\"k\">current asthma<\/td><td class=\"r\">1,932<\/td><td class=\"r\">2,099<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">541<\/td><td class=\"k\">hmlh<\/td><td class=\"r\">1,782<\/td><td class=\"r\">1,930<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">542<\/td><td class=\"k\">mcf-7 cancer cell<\/td><td class=\"r\">1,290<\/td><td class=\"r\">1,360<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">543<\/td><td class=\"k\">art initiation<\/td><td class=\"r\">3,883<\/td><td class=\"r\">4,110<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">544<\/td><td class=\"k\">hcv replication<\/td><td class=\"r\">2,191<\/td><td class=\"r\">2,386<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">545<\/td><td class=\"k\">esophageal cancer cell<\/td><td class=\"r\">1,795<\/td><td class=\"r\">1,945<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">546<\/td><td class=\"k\">influenza-like illness (ili)<\/td><td class=\"r\">1,300<\/td><td class=\"r\">1,372<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">547<\/td><td class=\"k\">mtb\/rif<\/td><td class=\"r\">1,943<\/td><td class=\"r\">2,112<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">548<\/td><td class=\"k\">her2-overexpressing<\/td><td class=\"r\">1,196<\/td><td class=\"r\">1,249<\/td><td class=\"r\">18.93<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">549<\/td><td class=\"k\">androgen-independent prostate cancer<\/td><td class=\"r\">1,243<\/td><td class=\"r\">1,305<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">550<\/td><td class=\"k\">direct-acting antivirals (daas)<\/td><td class=\"r\">1,216<\/td><td class=\"r\">1,273<\/td><td class=\"r\">18.93<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">551<\/td><td class=\"k\">chronic kidney disease stage<\/td><td class=\"r\">1,297<\/td><td class=\"r\">1,369<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">552<\/td><td class=\"k\">drug use disorder<\/td><td class=\"r\">1,439<\/td><td class=\"r\">1,536<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">553<\/td><td class=\"k\">in vitro anticancer activity<\/td><td class=\"r\">1,599<\/td><td class=\"r\">1,722<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">554<\/td><td class=\"k\">muscle-invasive bladder cancer<\/td><td class=\"r\">3,993<\/td><td class=\"r\">4,217<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">555<\/td><td class=\"k\">hepatitis e virus (hev)<\/td><td class=\"r\">3,489<\/td><td class=\"r\">3,732<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">556<\/td><td class=\"k\">recurrence-free survival rate<\/td><td class=\"r\">1,950<\/td><td class=\"r\">2,121<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">557<\/td><td class=\"k\">colorectal carcinoma (crc)<\/td><td class=\"r\">1,712<\/td><td class=\"r\">1,852<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">558<\/td><td class=\"k\">severe stroke<\/td><td class=\"r\">1,813<\/td><td class=\"r\">1,967<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">559<\/td><td class=\"k\">tb diagnosis<\/td><td class=\"r\">2,100<\/td><td class=\"r\">2,288<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">560<\/td><td class=\"k\">colorectal cancer liver metastases<\/td><td class=\"r\">1,223<\/td><td class=\"r\">1,282<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">561<\/td><td class=\"k\">hcv coinfection<\/td><td class=\"r\">1,165<\/td><td class=\"r\">1,213<\/td><td class=\"r\">18.93<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">562<\/td><td class=\"k\">human lung cancer cells<\/td><td class=\"r\">2,485<\/td><td class=\"r\">2,706<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">563<\/td><td class=\"k\">drug-resistant cancer<\/td><td class=\"r\">1,304<\/td><td class=\"r\">1,378<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">564<\/td><td class=\"k\">diffuse large b cell lymphoma (dlbcl)<\/td><td class=\"r\">1,354<\/td><td class=\"r\">1,437<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">565<\/td><td class=\"k\">braf inhibitor<\/td><td class=\"r\">2,360<\/td><td class=\"r\">2,572<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">566<\/td><td class=\"k\">adults with cancer<\/td><td class=\"r\">1,751<\/td><td class=\"r\">1,897<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">567<\/td><td class=\"k\">direct-acting antiviral agent<\/td><td class=\"r\">1,330<\/td><td class=\"r\">1,409<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">568<\/td><td class=\"k\">endovascular thrombectomy<\/td><td class=\"r\">1,505<\/td><td class=\"r\">1,614<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">569<\/td><td class=\"k\">cancer gene expression<\/td><td class=\"r\">2,257<\/td><td class=\"r\">2,461<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">570<\/td><td class=\"k\">clinicopathologic factors<\/td><td class=\"r\">2,740<\/td><td class=\"r\">2,976<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">571<\/td><td class=\"k\">hepatitis c virus (hcv) genotype<\/td><td class=\"r\">1,231<\/td><td class=\"r\">1,292<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">572<\/td><td class=\"k\">atezolizumab<\/td><td class=\"r\">2,267<\/td><td class=\"r\">2,472<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">573<\/td><td class=\"k\">highly pathogenic avian influenza<\/td><td class=\"r\">3,550<\/td><td class=\"r\">3,794<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">574<\/td><td class=\"k\">brca1 and brca2 mutation<\/td><td class=\"r\">1,268<\/td><td class=\"r\">1,336<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">575<\/td><td class=\"k\">breast cancer stem cell<\/td><td class=\"r\">1,865<\/td><td class=\"r\">2,027<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">576<\/td><td class=\"k\">liver cancer cells<\/td><td class=\"r\">3,197<\/td><td class=\"r\">3,445<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">577<\/td><td class=\"k\">tumor cell apoptosis<\/td><td class=\"r\">2,550<\/td><td class=\"r\">2,777<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">578<\/td><td class=\"k\">cancer targeted therapy<\/td><td class=\"r\">1,287<\/td><td class=\"r\">1,359<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">579<\/td><td class=\"k\">pancreatic cancer (pc)<\/td><td class=\"r\">2,742<\/td><td class=\"r\">2,980<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">580<\/td><td class=\"k\">recovery after stroke<\/td><td class=\"r\">1,670<\/td><td class=\"r\">1,806<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">581<\/td><td class=\"k\">response evaluation criteria in solid tumor<\/td><td class=\"r\">3,917<\/td><td class=\"r\">4,150<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">582<\/td><td class=\"k\">cvd mortality<\/td><td class=\"r\">2,718<\/td><td class=\"r\">2,955<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">583<\/td><td class=\"k\">child obesity<\/td><td class=\"r\">1,558<\/td><td class=\"r\">1,677<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">584<\/td><td class=\"k\">chronic hepatitis c infection<\/td><td class=\"r\">1,514<\/td><td class=\"r\">1,626<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">585<\/td><td class=\"k\">organ-confined<\/td><td class=\"r\">2,159<\/td><td class=\"r\">2,356<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">586<\/td><td class=\"k\">prostate cancer screening<\/td><td class=\"r\">2,557<\/td><td class=\"r\">2,786<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">587<\/td><td class=\"k\">adult congenital heart disease<\/td><td class=\"r\">1,800<\/td><td class=\"r\">1,955<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">588<\/td><td class=\"k\">artemisinin-based combination<\/td><td class=\"r\">1,742<\/td><td class=\"r\">1,889<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">589<\/td><td class=\"k\">nonsmall cell lung<\/td><td class=\"r\">3,412<\/td><td class=\"r\">3,662<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">590<\/td><td class=\"k\">22rv1<\/td><td class=\"r\">1,197<\/td><td class=\"r\">1,253<\/td><td class=\"r\">18.93<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">591<\/td><td class=\"k\">cancer registry data<\/td><td class=\"r\">2,392<\/td><td class=\"r\">2,610<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">592<\/td><td class=\"k\">ribavirin (rbv)<\/td><td class=\"r\">1,457<\/td><td class=\"r\">1,560<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">593<\/td><td class=\"k\">overall and disease-free survival<\/td><td class=\"r\">2,575<\/td><td class=\"r\">2,806<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">594<\/td><td class=\"k\">prostate cancer risk<\/td><td class=\"r\">3,860<\/td><td class=\"r\">4,098<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">595<\/td><td class=\"k\">in vitro anticancer<\/td><td class=\"r\">2,844<\/td><td class=\"r\">3,088<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">596<\/td><td class=\"k\">adult cancer survivors<\/td><td class=\"r\">1,053<\/td><td class=\"r\">1,081<\/td><td class=\"r\">18.93<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">597<\/td><td class=\"k\">clinically localized prostate cancer<\/td><td class=\"r\">2,101<\/td><td class=\"r\">2,293<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">598<\/td><td class=\"k\">influenza a (h1n1)<\/td><td class=\"r\">2,569<\/td><td class=\"r\">2,800<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">599<\/td><td class=\"k\">circumferential resection margin<\/td><td class=\"r\">1,221<\/td><td class=\"r\">1,282<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">600<\/td><td class=\"k\">melanoma progression<\/td><td class=\"r\">2,035<\/td><td class=\"r\">2,220<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">601<\/td><td class=\"k\">subtypes of breast cancer<\/td><td class=\"r\">1,743<\/td><td class=\"r\">1,891<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">602<\/td><td class=\"k\">pulmonary tuberculosis (ptb)<\/td><td class=\"r\">1,687<\/td><td class=\"r\">1,827<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">603<\/td><td class=\"k\">uterine cervical neoplasm<\/td><td class=\"r\">1,714<\/td><td class=\"r\">1,858<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">604<\/td><td class=\"k\">nnrtis<\/td><td class=\"r\">2,086<\/td><td class=\"r\">2,277<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">605<\/td><td class=\"k\">advanced hepatocellular carcinoma<\/td><td class=\"r\">3,404<\/td><td class=\"r\">3,656<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">606<\/td><td class=\"k\">hereditary breast and ovarian cancer<\/td><td class=\"r\">1,417<\/td><td class=\"r\">1,514<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">607<\/td><td class=\"k\">mda-mb-468<\/td><td class=\"r\">2,030<\/td><td class=\"r\">2,215<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">608<\/td><td class=\"k\">thyroid cancer cell<\/td><td class=\"r\">1,995<\/td><td class=\"r\">2,176<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">609<\/td><td class=\"k\">diffuse large b-cell lymphomas<\/td><td class=\"r\">1,283<\/td><td class=\"r\">1,356<\/td><td class=\"r\">18.93<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">610<\/td><td class=\"k\">asthma children<\/td><td class=\"r\">2,836<\/td><td class=\"r\">3,081<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">611<\/td><td class=\"k\">children with obesity<\/td><td class=\"r\">1,365<\/td><td class=\"r\">1,453<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">612<\/td><td class=\"k\">human gastric cancer cells<\/td><td class=\"r\">1,636<\/td><td class=\"r\">1,769<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">613<\/td><td class=\"k\">pcr rate<\/td><td class=\"r\">1,497<\/td><td class=\"r\">1,608<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">614<\/td><td class=\"k\">egfr-mutated<\/td><td class=\"r\">1,308<\/td><td class=\"r\">1,386<\/td><td class=\"r\">18.93<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">615<\/td><td class=\"k\">circulating tumor dna (ctdna)<\/td><td class=\"r\">2,007<\/td><td class=\"r\">2,190<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">616<\/td><td class=\"k\">platinum-resistant<\/td><td class=\"r\">1,544<\/td><td class=\"r\">1,663<\/td><td class=\"r\">18.93<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">617<\/td><td class=\"k\">hev infection<\/td><td class=\"r\">2,057<\/td><td class=\"r\">2,246<\/td><td class=\"r\">18.93<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">618<\/td><td class=\"k\">cancer quality of life<\/td><td class=\"r\">4,373<\/td><td class=\"r\">4,583<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">619<\/td><td class=\"k\">human pancreatic cancer cells<\/td><td class=\"r\">1,481<\/td><td class=\"r\">1,590<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">620<\/td><td class=\"k\">chronic kidney disease patient<\/td><td class=\"r\">3,057<\/td><td class=\"r\">3,310<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">621<\/td><td class=\"k\">stroke event<\/td><td class=\"r\">2,008<\/td><td class=\"r\">2,192<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">622<\/td><td class=\"k\">peginterferon<\/td><td class=\"r\">2,722<\/td><td class=\"r\">2,964<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">623<\/td><td class=\"k\">urinary bladder neoplasm<\/td><td class=\"r\">1,854<\/td><td class=\"r\">2,019<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">624<\/td><td class=\"k\">active surveillance (as)<\/td><td class=\"r\">1,137<\/td><td class=\"r\">1,183<\/td><td class=\"r\">18.92<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">625<\/td><td class=\"k\">breast cancer surgery<\/td><td class=\"r\">3,003<\/td><td class=\"r\">3,255<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">626<\/td><td class=\"k\">combination antiretroviral therapy<\/td><td class=\"r\">3,867<\/td><td class=\"r\">4,109<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">627<\/td><td class=\"k\">hbeag-negative<\/td><td class=\"r\">1,597<\/td><td class=\"r\">1,725<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">628<\/td><td class=\"k\">clinicopathologic factor<\/td><td class=\"r\">2,783<\/td><td class=\"r\">3,028<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">629<\/td><td class=\"k\">du145 cells<\/td><td class=\"r\">1,708<\/td><td class=\"r\">1,853<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">630<\/td><td class=\"k\">pc3 cells<\/td><td class=\"r\">2,553<\/td><td class=\"r\">2,786<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">631<\/td><td class=\"k\">reproductive healthcare<\/td><td class=\"r\">2,005<\/td><td class=\"r\">2,189<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">632<\/td><td class=\"k\">obesity and metabolic syndrome<\/td><td class=\"r\">2,075<\/td><td class=\"r\">2,267<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">633<\/td><td class=\"k\">middle east respiratory syndrome coronavirus<\/td><td class=\"r\">1,937<\/td><td class=\"r\">2,113<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">634<\/td><td class=\"k\">du145 cell<\/td><td class=\"r\">1,889<\/td><td class=\"r\">2,059<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">635<\/td><td class=\"k\">vitro anticancer activity<\/td><td class=\"r\">1,741<\/td><td class=\"r\">1,891<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">636<\/td><td class=\"k\">xenograft mice<\/td><td class=\"r\">1,588<\/td><td class=\"r\">1,715<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">637<\/td><td class=\"k\">axillary lymph node dissection (alnd)<\/td><td class=\"r\">1,346<\/td><td class=\"r\">1,432<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">638<\/td><td class=\"k\">clinically significant prostate cancer<\/td><td class=\"r\">1,264<\/td><td class=\"r\">1,335<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">639<\/td><td class=\"k\">type 2 diabetes (t2dm)<\/td><td class=\"r\">4,072<\/td><td class=\"r\">4,305<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">640<\/td><td class=\"k\">obesity and insulin resistance<\/td><td class=\"r\">3,638<\/td><td class=\"r\">3,890<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">641<\/td><td class=\"k\">acute stroke treatment<\/td><td class=\"r\">1,195<\/td><td class=\"r\">1,253<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">642<\/td><td class=\"k\">sh-sy5y neuroblastoma cells<\/td><td class=\"r\">1,504<\/td><td class=\"r\">1,618<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">643<\/td><td class=\"k\">panitumumab<\/td><td class=\"r\">1,866<\/td><td class=\"r\">2,034<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">644<\/td><td class=\"k\">lung cancer (lc)<\/td><td class=\"r\">1,533<\/td><td class=\"r\">1,652<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">645<\/td><td class=\"k\">metastasis prognosis<\/td><td class=\"r\">1,934<\/td><td class=\"r\">2,111<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">646<\/td><td class=\"k\">asthma exacerbations<\/td><td class=\"r\">4,136<\/td><td class=\"r\">4,367<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">647<\/td><td class=\"k\">ascvd<\/td><td class=\"r\">2,614<\/td><td class=\"r\">2,853<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">648<\/td><td class=\"k\">anti-cancer effects<\/td><td class=\"r\">3,731<\/td><td class=\"r\">3,982<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">649<\/td><td class=\"k\">high-grade serous<\/td><td class=\"r\">3,145<\/td><td class=\"r\">3,403<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">650<\/td><td class=\"k\">tobacco dependence<\/td><td class=\"r\">2,138<\/td><td class=\"r\">2,339<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">651<\/td><td class=\"k\">cancer survivorship<\/td><td class=\"r\">3,409<\/td><td class=\"r\">3,668<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">652<\/td><td class=\"k\">progression-free survival rate<\/td><td class=\"r\">2,116<\/td><td class=\"r\">2,315<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">653<\/td><td class=\"k\">baseline cd4<\/td><td class=\"r\">2,079<\/td><td class=\"r\">2,274<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">654<\/td><td class=\"k\">latent tb<\/td><td class=\"r\">2,345<\/td><td class=\"r\">2,566<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">655<\/td><td class=\"k\">international prognostic index (ipi)<\/td><td class=\"r\">1,143<\/td><td class=\"r\">1,192<\/td><td class=\"r\">18.92<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">656<\/td><td class=\"k\">anticancer therapeutics<\/td><td class=\"r\">1,562<\/td><td class=\"r\">1,687<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">657<\/td><td class=\"k\">post-stroke patient<\/td><td class=\"r\">1,773<\/td><td class=\"r\">1,930<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">658<\/td><td class=\"k\">clinicopathologic parameter<\/td><td class=\"r\">2,365<\/td><td class=\"r\">2,588<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">659<\/td><td class=\"k\">orthotopic xenograft<\/td><td class=\"r\">1,805<\/td><td class=\"r\">1,967<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">660<\/td><td class=\"k\">sorafenib treatment<\/td><td class=\"r\">1,171<\/td><td class=\"r\">1,226<\/td><td class=\"r\">18.92<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">661<\/td><td class=\"k\">programmed cell death protein 1<\/td><td class=\"r\">2,458<\/td><td class=\"r\">2,689<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">662<\/td><td class=\"k\">hcc cell lines<\/td><td class=\"r\">3,993<\/td><td class=\"r\">4,236<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">663<\/td><td class=\"k\">urinary bladder neoplasms<\/td><td class=\"r\">1,726<\/td><td class=\"r\">1,877<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">664<\/td><td class=\"k\">stroke, myocardial infarction<\/td><td class=\"r\">2,131<\/td><td class=\"r\">2,333<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">665<\/td><td class=\"k\">tyrosine kinase inhibitors (tki)<\/td><td class=\"r\">1,360<\/td><td class=\"r\">1,451<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">666<\/td><td class=\"k\">cancer cell cycle<\/td><td class=\"r\">2,111<\/td><td class=\"r\">2,311<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">667<\/td><td class=\"k\">hereditary breast<\/td><td class=\"r\">3,335<\/td><td class=\"r\">3,597<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">668<\/td><td class=\"k\">progression-free and overall survival<\/td><td class=\"r\">2,397<\/td><td class=\"r\">2,624<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">669<\/td><td class=\"k\">lymphovascular invasion (lvi)<\/td><td class=\"r\">1,099<\/td><td class=\"r\">1,140<\/td><td class=\"r\">18.92<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">670<\/td><td class=\"k\">imaging prostate cancer<\/td><td class=\"r\">1,164<\/td><td class=\"r\">1,218<\/td><td class=\"r\">18.92<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">671<\/td><td class=\"k\">substance use problem<\/td><td class=\"r\">1,555<\/td><td class=\"r\">1,680<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">672<\/td><td class=\"k\">lenvatinib<\/td><td class=\"r\">1,702<\/td><td class=\"r\">1,850<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">673<\/td><td class=\"k\">clinicopathologic parameters<\/td><td class=\"r\">2,344<\/td><td class=\"r\">2,567<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">674<\/td><td class=\"k\">urothelial carcinoma of the bladder<\/td><td class=\"r\">1,245<\/td><td class=\"r\">1,315<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">675<\/td><td class=\"k\">stroke risk factors<\/td><td class=\"r\">2,077<\/td><td class=\"r\">2,274<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">676<\/td><td class=\"k\">cancer theranostics<\/td><td class=\"r\">1,667<\/td><td class=\"r\">1,810<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">677<\/td><td class=\"k\">acute myeloid leukemia patient<\/td><td class=\"r\">1,435<\/td><td class=\"r\">1,540<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">678<\/td><td class=\"k\">androgen-deprivation<\/td><td class=\"r\">1,306<\/td><td class=\"r\">1,388<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">679<\/td><td class=\"k\">post-stroke patients<\/td><td class=\"r\">1,717<\/td><td class=\"r\">1,868<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">680<\/td><td class=\"k\">obesity risk<\/td><td class=\"r\">3,762<\/td><td class=\"r\">4,018<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">681<\/td><td class=\"k\">liver cancer cell line<\/td><td class=\"r\">1,427<\/td><td class=\"r\">1,531<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">682<\/td><td class=\"k\">mother-to-child transmission of hiv<\/td><td class=\"r\">1,593<\/td><td class=\"r\">1,725<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">683<\/td><td class=\"k\">first-line setting<\/td><td class=\"r\">1,237<\/td><td class=\"r\">1,306<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">684<\/td><td class=\"k\">metastatic non-small cell lung cancer<\/td><td class=\"r\">1,489<\/td><td class=\"r\">1,604<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">685<\/td><td class=\"k\">invasive coronary angiography<\/td><td class=\"r\">2,261<\/td><td class=\"r\">2,478<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">686<\/td><td class=\"k\">hiv antiretroviral therapy<\/td><td class=\"r\">1,070<\/td><td class=\"r\">1,106<\/td><td class=\"r\">18.92<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">687<\/td><td class=\"k\">lymph node metastasis (lnm)<\/td><td class=\"r\">1,741<\/td><td class=\"r\">1,896<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">688<\/td><td class=\"k\">insulin glargine<\/td><td class=\"r\">2,360<\/td><td class=\"r\">2,586<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">689<\/td><td class=\"k\">anti-hev<\/td><td class=\"r\">1,476<\/td><td class=\"r\">1,589<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">690<\/td><td class=\"k\">cancer disparities<\/td><td class=\"r\">1,341<\/td><td class=\"r\">1,430<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">691<\/td><td class=\"k\">ear cancer<\/td><td class=\"r\">1,706<\/td><td class=\"r\">1,856<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">692<\/td><td class=\"k\">neoadjuvant chemotherapy<\/td><td class=\"r\">3,487<\/td><td class=\"r\">3,751<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">693<\/td><td class=\"k\">clear cell renal cell carcinoma (ccrcc)<\/td><td class=\"r\">2,994<\/td><td class=\"r\">3,255<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">694<\/td><td class=\"k\">detectable viral load<\/td><td class=\"r\">1,930<\/td><td class=\"r\">2,111<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">695<\/td><td class=\"k\">r-chop<\/td><td class=\"r\">2,618<\/td><td class=\"r\">2,863<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">696<\/td><td class=\"k\">asthma care<\/td><td class=\"r\">1,945<\/td><td class=\"r\">2,128<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">697<\/td><td class=\"k\">insulin glargin<\/td><td class=\"r\">2,378<\/td><td class=\"r\">2,606<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">698<\/td><td class=\"k\">lung cancer prognosis<\/td><td class=\"r\">2,044<\/td><td class=\"r\">2,239<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">699<\/td><td class=\"k\">anti-cancer therapy<\/td><td class=\"r\">2,856<\/td><td class=\"r\">3,113<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">700<\/td><td class=\"k\">immunosuppressive tumor microenvironment<\/td><td class=\"r\">1,503<\/td><td class=\"r\">1,621<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">701<\/td><td class=\"k\">pre-exposure prophylaxis (prep)<\/td><td class=\"r\">3,104<\/td><td class=\"r\">3,368<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">702<\/td><td class=\"k\">stroke risk factor<\/td><td class=\"r\">2,424<\/td><td class=\"r\">2,656<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">703<\/td><td class=\"k\">brca1 brca2<\/td><td class=\"r\">1,865<\/td><td class=\"r\">2,038<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">704<\/td><td class=\"k\">cancer gene therapy<\/td><td class=\"r\">3,308<\/td><td class=\"r\">3,574<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">705<\/td><td class=\"k\">uterine cervical neoplasms<\/td><td class=\"r\">1,550<\/td><td class=\"r\">1,676<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">706<\/td><td class=\"k\">cervical cancer cell line<\/td><td class=\"r\">2,421<\/td><td class=\"r\">2,653<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">707<\/td><td class=\"k\">basal-like<\/td><td class=\"r\">3,229<\/td><td class=\"r\">3,495<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">708<\/td><td class=\"k\">asthma guideline<\/td><td class=\"r\">1,171<\/td><td class=\"r\">1,228<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">709<\/td><td class=\"k\">h1n1 pandemic<\/td><td class=\"r\">1,442<\/td><td class=\"r\">1,550<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">710<\/td><td class=\"k\">head and neck squamous cell carcinomas<\/td><td class=\"r\">2,192<\/td><td class=\"r\">2,404<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">711<\/td><td class=\"k\">definitive chemoradiotherapy<\/td><td class=\"r\">1,135<\/td><td class=\"r\">1,185<\/td><td class=\"r\">18.92<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">712<\/td><td class=\"k\">substance use problems<\/td><td class=\"r\">1,453<\/td><td class=\"r\">1,563<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">713<\/td><td class=\"k\">hiv-1 entry<\/td><td class=\"r\">1,195<\/td><td class=\"r\">1,257<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">714<\/td><td class=\"k\">hbv genotypes<\/td><td class=\"r\">1,179<\/td><td class=\"r\">1,238<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">715<\/td><td class=\"k\">xenograft growth<\/td><td class=\"r\">1,533<\/td><td class=\"r\">1,657<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">716<\/td><td class=\"k\">programmed death-ligand 1<\/td><td class=\"r\">3,109<\/td><td class=\"r\">3,375<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">717<\/td><td class=\"k\">hiv clinics<\/td><td class=\"r\">1,229<\/td><td class=\"r\">1,298<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">718<\/td><td class=\"k\">ovarian cancer (oc)<\/td><td class=\"r\">2,649<\/td><td class=\"r\">2,898<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">719<\/td><td class=\"k\">sentinel lymph nodes<\/td><td class=\"r\">3,510<\/td><td class=\"r\">3,777<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">720<\/td><td class=\"k\">inflammation and cancer<\/td><td class=\"r\">2,329<\/td><td class=\"r\">2,555<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">721<\/td><td class=\"k\">hiv risk behavior<\/td><td class=\"r\">1,969<\/td><td class=\"r\">2,157<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">722<\/td><td class=\"k\">advanced\/metastatic<\/td><td class=\"r\">1,142<\/td><td class=\"r\">1,194<\/td><td class=\"r\">18.92<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">723<\/td><td class=\"k\">programmed death ligand 1<\/td><td class=\"r\">2,035<\/td><td class=\"r\">2,231<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">724<\/td><td class=\"k\">hereditary breast cancer<\/td><td class=\"r\">1,506<\/td><td class=\"r\">1,626<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">725<\/td><td class=\"k\">egfr-mutant<\/td><td class=\"r\">1,541<\/td><td class=\"r\">1,667<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">726<\/td><td class=\"k\">ovarian cancer risk<\/td><td class=\"r\">1,798<\/td><td class=\"r\">1,964<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">727<\/td><td class=\"k\">metastatic pancreatic cancer<\/td><td class=\"r\">1,563<\/td><td class=\"r\">1,693<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">728<\/td><td class=\"k\">brca mutations<\/td><td class=\"r\">1,314<\/td><td class=\"r\">1,400<\/td><td class=\"r\">18.92<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">729<\/td><td class=\"k\">high hiv prevalence<\/td><td class=\"r\">1,423<\/td><td class=\"r\">1,529<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">730<\/td><td class=\"k\">antenatal care (anc)<\/td><td class=\"r\">2,020<\/td><td class=\"r\">2,215<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">731<\/td><td class=\"k\">k103n<\/td><td class=\"r\">994<\/td><td class=\"r\">1,016<\/td><td class=\"r\">18.92<\/td><td class=\"r\">98%<\/td><\/tr><tr><td class=\"r\">732<\/td><td class=\"k\">hiv drug resistance<\/td><td class=\"r\">1,456<\/td><td class=\"r\">1,568<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">733<\/td><td class=\"k\">substance use disorder treatment<\/td><td class=\"r\">1,144<\/td><td class=\"r\">1,197<\/td><td class=\"r\">18.92<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">734<\/td><td class=\"k\">long-acting reversible<\/td><td class=\"r\">1,610<\/td><td class=\"r\">1,748<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">735<\/td><td class=\"k\">obesity and overweight<\/td><td class=\"r\">2,198<\/td><td class=\"r\">2,413<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">736<\/td><td class=\"k\">hiv services<\/td><td class=\"r\">1,609<\/td><td class=\"r\">1,747<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">737<\/td><td class=\"k\">cervical cancer prevention<\/td><td class=\"r\">1,766<\/td><td class=\"r\">1,928<\/td><td class=\"r\">18.92<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">738<\/td><td class=\"k\">breslow thickness<\/td><td class=\"r\">1,491<\/td><td class=\"r\">1,610<\/td><td class=\"r\">18.92<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">739<\/td><td class=\"k\">raltegravir<\/td><td class=\"r\">1,875<\/td><td class=\"r\">2,053<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">740<\/td><td class=\"k\">ras wild-type<\/td><td class=\"r\">1,200<\/td><td class=\"r\">1,265<\/td><td class=\"r\">18.92<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">741<\/td><td class=\"k\">plasma viral load<\/td><td class=\"r\">2,297<\/td><td class=\"r\">2,523<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">742<\/td><td class=\"k\">osimertinib<\/td><td class=\"r\">1,989<\/td><td class=\"r\">2,182<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">743<\/td><td class=\"k\">pre-diabetes<\/td><td class=\"r\">2,421<\/td><td class=\"r\">2,658<\/td><td class=\"r\">18.92<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">744<\/td><td class=\"k\">non-small cell lung cancer patients<\/td><td class=\"r\">3,484<\/td><td class=\"r\">3,756<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">745<\/td><td class=\"k\">colorectal cancer surgery<\/td><td class=\"r\">1,665<\/td><td class=\"r\">1,813<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">746<\/td><td class=\"k\">recurrence survival<\/td><td class=\"r\">1,723<\/td><td class=\"r\">1,880<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">747<\/td><td class=\"k\">significant cancer<\/td><td class=\"r\">1,376<\/td><td class=\"r\">1,475<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">748<\/td><td class=\"k\">epithelial\u2013mesenchymal transition (emt)<\/td><td class=\"r\">2,312<\/td><td class=\"r\">2,540<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">749<\/td><td class=\"k\">melanoma treatment<\/td><td class=\"r\">1,569<\/td><td class=\"r\">1,702<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">750<\/td><td class=\"k\">aml cell lines<\/td><td class=\"r\">1,326<\/td><td class=\"r\">1,416<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">751<\/td><td class=\"k\">hiv-1 vaccine<\/td><td class=\"r\">1,611<\/td><td class=\"r\">1,751<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">752<\/td><td class=\"k\">viral load (vl)<\/td><td class=\"r\">1,881<\/td><td class=\"r\">2,061<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">753<\/td><td class=\"k\">chemoradiation therapy<\/td><td class=\"r\">3,380<\/td><td class=\"r\">3,654<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">754<\/td><td class=\"k\">hiv diagnosis<\/td><td class=\"r\">3,926<\/td><td class=\"r\">4,187<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">755<\/td><td class=\"k\">paclitaxel and carboplatin<\/td><td class=\"r\">1,211<\/td><td class=\"r\">1,279<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">756<\/td><td class=\"k\">hev rna<\/td><td class=\"r\">1,107<\/td><td class=\"r\">1,154<\/td><td class=\"r\">18.91<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">757<\/td><td class=\"k\">rectal cancer treatment<\/td><td class=\"r\">1,433<\/td><td class=\"r\">1,543<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">758<\/td><td class=\"k\">influenza a virus (iav)<\/td><td class=\"r\">2,208<\/td><td class=\"r\">2,427<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">759<\/td><td class=\"k\">human liver cancer<\/td><td class=\"r\">2,010<\/td><td class=\"r\">2,207<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">760<\/td><td class=\"k\">rectal cancer resection<\/td><td class=\"r\">1,116<\/td><td class=\"r\">1,165<\/td><td class=\"r\">18.91<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">761<\/td><td class=\"k\">sporadic colorectal cancer<\/td><td class=\"r\">1,414<\/td><td class=\"r\">1,521<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">762<\/td><td class=\"k\">prostate cancer cell lines<\/td><td class=\"r\">4,375<\/td><td class=\"r\">4,611<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">763<\/td><td class=\"k\">serous ovarian cancer<\/td><td class=\"r\">2,455<\/td><td class=\"r\">2,697<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">764<\/td><td class=\"k\">pcnsl<\/td><td class=\"r\">1,980<\/td><td class=\"r\">2,174<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">765<\/td><td class=\"k\">breast cancer xenograft<\/td><td class=\"r\">1,369<\/td><td class=\"r\">1,468<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">766<\/td><td class=\"k\">human pancreatic cancer cell<\/td><td class=\"r\">2,547<\/td><td class=\"r\">2,796<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">767<\/td><td class=\"k\">methicillin-resistant s. aureus (mrsa)<\/td><td class=\"r\">2,827<\/td><td class=\"r\">3,092<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">768<\/td><td class=\"k\">hiv-1-infected patients<\/td><td class=\"r\">2,742<\/td><td class=\"r\">3,003<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">769<\/td><td class=\"k\">cancer stem cell marker<\/td><td class=\"r\">1,373<\/td><td class=\"r\">1,473<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">770<\/td><td class=\"k\">advanced rectal cancer<\/td><td class=\"r\">4,126<\/td><td class=\"r\">4,380<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">771<\/td><td class=\"k\">lymph node staging<\/td><td class=\"r\">1,512<\/td><td class=\"r\">1,637<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">772<\/td><td class=\"k\">stroke outcome<\/td><td class=\"r\">4,016<\/td><td class=\"r\">4,276<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">773<\/td><td class=\"k\">obesity intervention<\/td><td class=\"r\">1,176<\/td><td class=\"r\">1,238<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">774<\/td><td class=\"k\">retention in care<\/td><td class=\"r\">1,535<\/td><td class=\"r\">1,664<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">775<\/td><td class=\"k\">post stroke<\/td><td class=\"r\">2,370<\/td><td class=\"r\">2,606<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">776<\/td><td class=\"k\">overweight or obesity<\/td><td class=\"r\">4,023<\/td><td class=\"r\">4,283<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">777<\/td><td class=\"k\">triple negative breast cancer (tnbc)<\/td><td class=\"r\">2,229<\/td><td class=\"r\">2,452<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">778<\/td><td class=\"k\">complicated malaria<\/td><td class=\"r\">2,188<\/td><td class=\"r\">2,407<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">779<\/td><td class=\"k\">gleason grade<\/td><td class=\"r\">2,422<\/td><td class=\"r\">2,663<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">780<\/td><td class=\"k\">breast cancer recurrence<\/td><td class=\"r\">2,025<\/td><td class=\"r\">2,226<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">781<\/td><td class=\"k\">novel anticancer agent<\/td><td class=\"r\">1,379<\/td><td class=\"r\">1,481<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">782<\/td><td class=\"k\">nucleos(t)ide analogue<\/td><td class=\"r\">1,253<\/td><td class=\"r\">1,331<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">783<\/td><td class=\"k\">non-small cell lung cancer cell<\/td><td class=\"r\">3,014<\/td><td class=\"r\">3,288<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">784<\/td><td class=\"k\">avian influenza viruses<\/td><td class=\"r\">2,943<\/td><td class=\"r\">3,215<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">785<\/td><td class=\"k\">chemical failure<\/td><td class=\"r\">2,179<\/td><td class=\"r\">2,398<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">786<\/td><td class=\"k\">cannabis use disorder<\/td><td class=\"r\">1,405<\/td><td class=\"r\">1,512<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">787<\/td><td class=\"k\">papillary thyroid carcinoma (ptc)<\/td><td class=\"r\">4,267<\/td><td class=\"r\">4,515<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">788<\/td><td class=\"k\">asthma prevalence<\/td><td class=\"r\">1,774<\/td><td class=\"r\">1,942<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">789<\/td><td class=\"k\">radical cystectomy (rc)<\/td><td class=\"r\">1,516<\/td><td class=\"r\">1,643<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">790<\/td><td class=\"k\">anaplastic thyroid cancer<\/td><td class=\"r\">1,318<\/td><td class=\"r\">1,409<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">791<\/td><td class=\"k\">breast cancer therapy<\/td><td class=\"r\">3,140<\/td><td class=\"r\">3,418<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">792<\/td><td class=\"k\">ecog ps<\/td><td class=\"r\">1,265<\/td><td class=\"r\">1,346<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">793<\/td><td class=\"k\">triple-negative breast cancers<\/td><td class=\"r\">1,159<\/td><td class=\"r\">1,219<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">794<\/td><td class=\"k\">breast cancer stem cells<\/td><td class=\"r\">1,553<\/td><td class=\"r\">1,687<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">795<\/td><td class=\"k\">her2+<\/td><td class=\"r\">3,392<\/td><td class=\"r\">3,673<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">796<\/td><td class=\"k\">kidney disease progression<\/td><td class=\"r\">1,284<\/td><td class=\"r\">1,369<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">797<\/td><td class=\"k\">direct acting antiviral<\/td><td class=\"r\">1,460<\/td><td class=\"r\">1,578<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">798<\/td><td class=\"k\">hiv knowledge<\/td><td class=\"r\">1,426<\/td><td class=\"r\">1,538<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">799<\/td><td class=\"k\">cancer stemness<\/td><td class=\"r\">1,504<\/td><td class=\"r\">1,630<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">800<\/td><td class=\"k\">platinum-sensitive<\/td><td class=\"r\">1,221<\/td><td class=\"r\">1,294<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">801<\/td><td class=\"k\">cause-specific survival<\/td><td class=\"r\">2,141<\/td><td class=\"r\">2,358<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">802<\/td><td class=\"k\">xenograft tumors<\/td><td class=\"r\">3,825<\/td><td class=\"r\">4,099<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">803<\/td><td class=\"k\">exon 19 deletion<\/td><td class=\"r\">1,181<\/td><td class=\"r\">1,246<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">804<\/td><td class=\"k\">transcatheter arterial chemoembolization<\/td><td class=\"r\">2,914<\/td><td class=\"r\">3,188<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">805<\/td><td class=\"k\">osteosarcoma (os)<\/td><td class=\"r\">2,965<\/td><td class=\"r\">3,241<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">806<\/td><td class=\"k\">human gastric cancer cell<\/td><td class=\"r\">2,961<\/td><td class=\"r\">3,237<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">807<\/td><td class=\"k\">dengue virus (denv)<\/td><td class=\"r\">3,760<\/td><td class=\"r\">4,037<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">808<\/td><td class=\"k\">kidney disease: improving global outcomes<\/td><td class=\"r\">1,199<\/td><td class=\"r\">1,268<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">809<\/td><td class=\"k\">checkpoint inhibition<\/td><td class=\"r\">2,370<\/td><td class=\"r\">2,611<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">810<\/td><td class=\"k\">stroke recovery<\/td><td class=\"r\">2,325<\/td><td class=\"r\">2,562<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">811<\/td><td class=\"k\">tumor xenograft model<\/td><td class=\"r\">1,933<\/td><td class=\"r\">2,126<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">812<\/td><td class=\"k\">mda-mb-435<\/td><td class=\"r\">1,585<\/td><td class=\"r\">1,726<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">813<\/td><td class=\"k\">bcr-abl1<\/td><td class=\"r\">2,018<\/td><td class=\"r\">2,222<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">814<\/td><td class=\"k\">hepatocellular carcinoma cell line<\/td><td class=\"r\">2,280<\/td><td class=\"r\">2,513<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">815<\/td><td class=\"k\">papillary renal cell carcinoma<\/td><td class=\"r\">1,441<\/td><td class=\"r\">1,557<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">816<\/td><td class=\"k\">coronary artery calcium (cac)<\/td><td class=\"r\">1,463<\/td><td class=\"r\">1,583<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">817<\/td><td class=\"k\">asthma risk<\/td><td class=\"r\">1,261<\/td><td class=\"r\">1,343<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">818<\/td><td class=\"k\">tumor-associated macrophages (tams)<\/td><td class=\"r\">2,508<\/td><td class=\"r\">2,761<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">819<\/td><td class=\"k\">hiv-positive men<\/td><td class=\"r\">1,364<\/td><td class=\"r\">1,466<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">820<\/td><td class=\"k\">entecavir<\/td><td class=\"r\">2,958<\/td><td class=\"r\">3,236<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">821<\/td><td class=\"k\">du-145<\/td><td class=\"r\">2,095<\/td><td class=\"r\">2,309<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">822<\/td><td class=\"k\">cancer strategy<\/td><td class=\"r\">1,233<\/td><td class=\"r\">1,310<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">823<\/td><td class=\"k\">disease-free and overall survival<\/td><td class=\"r\">2,602<\/td><td class=\"r\">2,863<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">824<\/td><td class=\"k\">drug-resistant tb<\/td><td class=\"r\">2,285<\/td><td class=\"r\">2,520<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">825<\/td><td class=\"k\">ajcc stage<\/td><td class=\"r\">1,572<\/td><td class=\"r\">1,712<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">826<\/td><td class=\"k\">aggressive prostate cancer<\/td><td class=\"r\">1,227<\/td><td class=\"r\">1,303<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">827<\/td><td class=\"k\">panc-1 cells<\/td><td class=\"r\">1,644<\/td><td class=\"r\">1,796<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">828<\/td><td class=\"k\">secondary stroke prevention<\/td><td class=\"r\">1,267<\/td><td class=\"r\">1,351<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">829<\/td><td class=\"k\">small cell lung cancer cells<\/td><td class=\"r\">2,488<\/td><td class=\"r\">2,741<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">830<\/td><td class=\"k\">ns5a<\/td><td class=\"r\">2,710<\/td><td class=\"r\">2,978<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">831<\/td><td class=\"k\">diabetes self-care<\/td><td class=\"r\">1,365<\/td><td class=\"r\">1,468<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">832<\/td><td class=\"k\">cancer outcomes<\/td><td class=\"r\">4,317<\/td><td class=\"r\">4,571<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">833<\/td><td class=\"k\">pathological complete response<\/td><td class=\"r\">3,893<\/td><td class=\"r\">4,170<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">834<\/td><td class=\"k\">human non-small cell lung cancer<\/td><td class=\"r\">1,839<\/td><td class=\"r\">2,021<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">835<\/td><td class=\"k\">clinicopathological variables<\/td><td class=\"r\">2,637<\/td><td class=\"r\">2,901<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">836<\/td><td class=\"k\">oncolytic adenovirus<\/td><td class=\"r\">1,369<\/td><td class=\"r\">1,473<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">837<\/td><td class=\"k\">global initiative for asthma<\/td><td class=\"r\">1,071<\/td><td class=\"r\">1,115<\/td><td class=\"r\">18.91<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">838<\/td><td class=\"k\">androgen-deprivation therapy<\/td><td class=\"r\">1,186<\/td><td class=\"r\">1,254<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">839<\/td><td class=\"k\">esophageal cancer patients<\/td><td class=\"r\">2,619<\/td><td class=\"r\">2,882<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">840<\/td><td class=\"k\">kras mutations<\/td><td class=\"r\">3,499<\/td><td class=\"r\">3,786<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">841<\/td><td class=\"k\">carcinoma hepatocellular<\/td><td class=\"r\">3,251<\/td><td class=\"r\">3,538<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">842<\/td><td class=\"k\">cardioembolic stroke<\/td><td class=\"r\">2,024<\/td><td class=\"r\">2,231<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">843<\/td><td class=\"k\">clinicopathological variable<\/td><td class=\"r\">2,677<\/td><td class=\"r\">2,944<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">844<\/td><td class=\"k\">panc-1 cell<\/td><td class=\"r\">1,850<\/td><td class=\"r\">2,034<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">845<\/td><td class=\"k\">syntax score<\/td><td class=\"r\">1,621<\/td><td class=\"r\">1,770<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">846<\/td><td class=\"k\">non-muscle invasive bladder cancer<\/td><td class=\"r\">1,383<\/td><td class=\"r\">1,490<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">847<\/td><td class=\"k\">recist criteria<\/td><td class=\"r\">1,279<\/td><td class=\"r\">1,366<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">848<\/td><td class=\"k\">stroke care<\/td><td class=\"r\">3,790<\/td><td class=\"r\">4,072<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">849<\/td><td class=\"k\">xpert mtb\/rif<\/td><td class=\"r\">1,620<\/td><td class=\"r\">1,769<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">850<\/td><td class=\"k\">incident cancer<\/td><td class=\"r\">1,572<\/td><td class=\"r\">1,713<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">851<\/td><td class=\"k\">scchn<\/td><td class=\"r\">1,675<\/td><td class=\"r\">1,833<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">852<\/td><td class=\"k\">high-risk neuroblastoma<\/td><td class=\"r\">1,258<\/td><td class=\"r\">1,341<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">853<\/td><td class=\"k\">hepatitis g virus<\/td><td class=\"r\">1,008<\/td><td class=\"r\">1,039<\/td><td class=\"r\">18.91<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">854<\/td><td class=\"k\">hbv reactivation<\/td><td class=\"r\">1,193<\/td><td class=\"r\">1,263<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">855<\/td><td class=\"k\">primary hcc<\/td><td class=\"r\">1,242<\/td><td class=\"r\">1,322<\/td><td class=\"r\">18.91<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">856<\/td><td class=\"k\">diabetes prevention<\/td><td class=\"r\">3,956<\/td><td class=\"r\">4,233<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">857<\/td><td class=\"k\">human cervical cancer<\/td><td class=\"r\">3,143<\/td><td class=\"r\">3,430<\/td><td class=\"r\">18.91<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">858<\/td><td class=\"k\">pik3ca mutation<\/td><td class=\"r\">1,922<\/td><td class=\"r\">2,117<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">859<\/td><td class=\"k\">people with stroke<\/td><td class=\"r\">1,177<\/td><td class=\"r\">1,244<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">860<\/td><td class=\"k\">metastasis-free survival<\/td><td class=\"r\">4,475<\/td><td class=\"r\">4,721<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">861<\/td><td class=\"k\">xpert mtb<\/td><td class=\"r\">1,670<\/td><td class=\"r\">1,828<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">862<\/td><td class=\"k\">egfr tyrosine kinase<\/td><td class=\"r\">3,736<\/td><td class=\"r\">4,022<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">863<\/td><td class=\"k\">anthracycline-based chemotherapy<\/td><td class=\"r\">1,113<\/td><td class=\"r\">1,167<\/td><td class=\"r\">18.91<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">864<\/td><td class=\"k\">brafv600e<\/td><td class=\"r\">2,404<\/td><td class=\"r\">2,653<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">865<\/td><td class=\"k\">anti-tuberculosis treatment<\/td><td class=\"r\">1,325<\/td><td class=\"r\">1,422<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">866<\/td><td class=\"k\">highly pathogenic avian influenza (hpai)<\/td><td class=\"r\">1,335<\/td><td class=\"r\">1,434<\/td><td class=\"r\">18.91<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">867<\/td><td class=\"k\">anti-pd-l1<\/td><td class=\"r\">2,401<\/td><td class=\"r\">2,650<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">868<\/td><td class=\"k\">raf inhibitors<\/td><td class=\"r\">1,717<\/td><td class=\"r\">1,883<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">869<\/td><td class=\"k\">cancer thyroid<\/td><td class=\"r\">2,097<\/td><td class=\"r\">2,315<\/td><td class=\"r\">18.91<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">870<\/td><td class=\"k\">children obesity<\/td><td class=\"r\">1,318<\/td><td class=\"r\">1,414<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">871<\/td><td class=\"k\">nonsmall cell<\/td><td class=\"r\">3,515<\/td><td class=\"r\">3,806<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">872<\/td><td class=\"k\">non-small cell lung carcinoma (nsclc)<\/td><td class=\"r\">1,450<\/td><td class=\"r\">1,571<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">873<\/td><td class=\"k\">type 2 diabetes risk<\/td><td class=\"r\">1,247<\/td><td class=\"r\">1,329<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">874<\/td><td class=\"k\">psma pet<\/td><td class=\"r\">1,272<\/td><td class=\"r\">1,359<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">875<\/td><td class=\"k\">asthma medication<\/td><td class=\"r\">2,556<\/td><td class=\"r\">2,818<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">876<\/td><td class=\"k\">pneumonia severity<\/td><td class=\"r\">1,227<\/td><td class=\"r\">1,305<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">877<\/td><td class=\"k\">dipeptidyl peptidase-4 inhibitor<\/td><td class=\"r\">2,361<\/td><td class=\"r\">2,607<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">878<\/td><td class=\"k\">esat-6<\/td><td class=\"r\">1,477<\/td><td class=\"r\">1,603<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">879<\/td><td class=\"k\">direct-acting antiviral agents<\/td><td class=\"r\">1,211<\/td><td class=\"r\">1,286<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">880<\/td><td class=\"k\">national comprehensive cancer network (nccn)<\/td><td class=\"r\">1,133<\/td><td class=\"r\">1,192<\/td><td class=\"r\">18.9<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">881<\/td><td class=\"k\">egfr inhibitors<\/td><td class=\"r\">2,708<\/td><td class=\"r\">2,981<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">882<\/td><td class=\"k\">programmed death-ligand<\/td><td class=\"r\">3,238<\/td><td class=\"r\">3,530<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">883<\/td><td class=\"k\">breast cancer cell proliferation<\/td><td class=\"r\">1,878<\/td><td class=\"r\">2,069<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">884<\/td><td class=\"k\">anticancer treatments<\/td><td class=\"r\">1,501<\/td><td class=\"r\">1,632<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">885<\/td><td class=\"k\">type 1 dm<\/td><td class=\"r\">1,397<\/td><td class=\"r\">1,509<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">886<\/td><td class=\"k\">egfr-tki<\/td><td class=\"r\">4,172<\/td><td class=\"r\">4,443<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">887<\/td><td class=\"k\">vascular space invasion<\/td><td class=\"r\">1,456<\/td><td class=\"r\">1,579<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">888<\/td><td class=\"k\">metastasectomy<\/td><td class=\"r\">2,635<\/td><td class=\"r\">2,904<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">889<\/td><td class=\"k\">middle east respiratory syndrome coronavirus (mers-cov)<\/td><td class=\"r\">1,407<\/td><td class=\"r\">1,521<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">890<\/td><td class=\"k\">cancer intervention<\/td><td class=\"r\">1,528<\/td><td class=\"r\">1,664<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">891<\/td><td class=\"k\">cancer aggressiveness<\/td><td class=\"r\">1,401<\/td><td class=\"r\">1,514<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">892<\/td><td class=\"k\">type 2 diabetic rat<\/td><td class=\"r\">1,669<\/td><td class=\"r\">1,829<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">893<\/td><td class=\"k\">incident cardiovascular disease<\/td><td class=\"r\">1,121<\/td><td class=\"r\">1,178<\/td><td class=\"r\">18.9<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">894<\/td><td class=\"k\">csc marker<\/td><td class=\"r\">1,236<\/td><td class=\"r\">1,317<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">895<\/td><td class=\"k\">oral cancer cells<\/td><td class=\"r\">1,231<\/td><td class=\"r\">1,311<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">896<\/td><td class=\"k\">hcc diagnosis<\/td><td class=\"r\">1,162<\/td><td class=\"r\">1,228<\/td><td class=\"r\">18.9<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">897<\/td><td class=\"k\">late toxicities<\/td><td class=\"r\">1,696<\/td><td class=\"r\">1,861<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">898<\/td><td class=\"k\">crizotinib<\/td><td class=\"r\">2,778<\/td><td class=\"r\">3,057<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">899<\/td><td class=\"k\">breast and prostate cancer<\/td><td class=\"r\">2,480<\/td><td class=\"r\">2,739<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">900<\/td><td class=\"k\">cancer resistance<\/td><td class=\"r\">4,144<\/td><td class=\"r\">4,419<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">901<\/td><td class=\"k\">b-cell lymphoma 2 (bcl-2)<\/td><td class=\"r\">1,478<\/td><td class=\"r\">1,606<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">902<\/td><td class=\"k\">pulmonary tuberculosis (tb)<\/td><td class=\"r\">1,701<\/td><td class=\"r\">1,867<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">903<\/td><td class=\"k\">quantiferon<\/td><td class=\"r\">2,175<\/td><td class=\"r\">2,405<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">904<\/td><td class=\"k\">cardiovascular and cerebrovascular diseases<\/td><td class=\"r\">1,528<\/td><td class=\"r\">1,665<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">905<\/td><td class=\"k\">oncogenic function<\/td><td class=\"r\">2,211<\/td><td class=\"r\">2,445<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">906<\/td><td class=\"k\">disease-specific survival rate<\/td><td class=\"r\">1,118<\/td><td class=\"r\">1,175<\/td><td class=\"r\">18.9<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">907<\/td><td class=\"k\">lung cancer a549 cell<\/td><td class=\"r\">1,174<\/td><td class=\"r\">1,243<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">908<\/td><td class=\"k\">usual interstitial pneumonia<\/td><td class=\"r\">1,755<\/td><td class=\"r\">1,930<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">909<\/td><td class=\"k\">adherence to antiretroviral therapy<\/td><td class=\"r\">1,368<\/td><td class=\"r\">1,476<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">910<\/td><td class=\"k\">rassf1<\/td><td class=\"r\">1,869<\/td><td class=\"r\">2,061<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">911<\/td><td class=\"k\">diabetes mellitus type 1<\/td><td class=\"r\">1,848<\/td><td class=\"r\">2,037<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">912<\/td><td class=\"k\">antiretroviral medication<\/td><td class=\"r\">1,588<\/td><td class=\"r\">1,736<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">913<\/td><td class=\"k\">er-positive breast cancer<\/td><td class=\"r\">1,357<\/td><td class=\"r\">1,463<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">914<\/td><td class=\"k\">micropapillary<\/td><td class=\"r\">1,903<\/td><td class=\"r\">2,100<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">915<\/td><td class=\"k\">immune-related adverse events (iraes)<\/td><td class=\"r\">1,628<\/td><td class=\"r\">1,783<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">916<\/td><td class=\"k\">laryngeal squamous cell carcinoma<\/td><td class=\"r\">2,495<\/td><td class=\"r\">2,757<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">917<\/td><td class=\"k\">advanced melanoma<\/td><td class=\"r\">3,106<\/td><td class=\"r\">3,400<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">918<\/td><td class=\"k\">tumor necrosis factor-related<\/td><td class=\"r\">2,947<\/td><td class=\"r\">3,236<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">919<\/td><td class=\"k\">the cancer genome atlas database<\/td><td class=\"r\">1,573<\/td><td class=\"r\">1,719<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">920<\/td><td class=\"k\">latent tb infection<\/td><td class=\"r\">1,550<\/td><td class=\"r\">1,692<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">921<\/td><td class=\"k\">cancer information<\/td><td class=\"r\">1,631<\/td><td class=\"r\">1,787<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">922<\/td><td class=\"k\">hormone receptor (hr)<\/td><td class=\"r\">1,100<\/td><td class=\"r\">1,154<\/td><td class=\"r\">18.9<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">923<\/td><td class=\"k\">type 1 diabetes patients<\/td><td class=\"r\">1,209<\/td><td class=\"r\">1,286<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">924<\/td><td class=\"k\">alcohol-dependent patients<\/td><td class=\"r\">1,427<\/td><td class=\"r\">1,547<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">925<\/td><td class=\"k\">advanced esophageal cancer<\/td><td class=\"r\">1,514<\/td><td class=\"r\">1,650<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">926<\/td><td class=\"k\">afatinib<\/td><td class=\"r\">1,813<\/td><td class=\"r\">1,998<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">927<\/td><td class=\"k\">relapse-free survival (rfs)<\/td><td class=\"r\">2,369<\/td><td class=\"r\">2,621<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">928<\/td><td class=\"k\">suicide ideation<\/td><td class=\"r\">3,372<\/td><td class=\"r\">3,671<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">929<\/td><td class=\"k\">m184v<\/td><td class=\"r\">1,025<\/td><td class=\"r\">1,063<\/td><td class=\"r\">18.9<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">930<\/td><td class=\"k\">brafv600<\/td><td class=\"r\">2,704<\/td><td class=\"r\">2,982<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">931<\/td><td class=\"k\">cancer pathogenesis<\/td><td class=\"r\">3,178<\/td><td class=\"r\">3,475<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">932<\/td><td class=\"k\">cancer diagnoses<\/td><td class=\"r\">3,131<\/td><td class=\"r\">3,427<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">933<\/td><td class=\"k\">antiretroviral (arv)<\/td><td class=\"r\">1,634<\/td><td class=\"r\">1,791<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">934<\/td><td class=\"k\">stroke management<\/td><td class=\"r\">1,628<\/td><td class=\"r\">1,784<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">935<\/td><td class=\"k\">severe maternal morbidity<\/td><td class=\"r\">1,103<\/td><td class=\"r\">1,158<\/td><td class=\"r\">18.9<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">936<\/td><td class=\"k\">stage iiic<\/td><td class=\"r\">1,657<\/td><td class=\"r\">1,818<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">937<\/td><td class=\"k\">adult congenital heart<\/td><td class=\"r\">1,878<\/td><td class=\"r\">2,073<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">938<\/td><td class=\"k\">advanced pancreatic cancer<\/td><td class=\"r\">3,273<\/td><td class=\"r\">3,572<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">939<\/td><td class=\"k\">malt lymphoma<\/td><td class=\"r\">3,411<\/td><td class=\"r\">3,711<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">940<\/td><td class=\"k\">pdac cells<\/td><td class=\"r\">1,494<\/td><td class=\"r\">1,627<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">941<\/td><td class=\"k\">plhiv<\/td><td class=\"r\">2,307<\/td><td class=\"r\">2,554<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">942<\/td><td class=\"k\">cancer resection<\/td><td class=\"r\">3,638<\/td><td class=\"r\">3,937<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">943<\/td><td class=\"k\">obesity-related disease<\/td><td class=\"r\">1,293<\/td><td class=\"r\">1,388<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">944<\/td><td class=\"k\">cancer cell invasion<\/td><td class=\"r\">3,457<\/td><td class=\"r\">3,758<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">945<\/td><td class=\"k\">downstaging<\/td><td class=\"r\">2,816<\/td><td class=\"r\">3,102<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">946<\/td><td class=\"k\">anti-her2<\/td><td class=\"r\">3,240<\/td><td class=\"r\">3,540<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">947<\/td><td class=\"k\">pc-3 cells<\/td><td class=\"r\">3,826<\/td><td class=\"r\">4,122<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">948<\/td><td class=\"k\">simert<\/td><td class=\"r\">1,992<\/td><td class=\"r\">2,204<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">949<\/td><td class=\"k\">glargine<\/td><td class=\"r\">2,980<\/td><td class=\"r\">3,274<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">950<\/td><td class=\"k\">castration resistant<\/td><td class=\"r\">1,346<\/td><td class=\"r\">1,452<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">951<\/td><td class=\"k\">pediatric acute lymphoblastic leukemia<\/td><td class=\"r\">1,212<\/td><td class=\"r\">1,291<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">952<\/td><td class=\"k\">immune-checkpoint<\/td><td class=\"r\">1,729<\/td><td class=\"r\">1,903<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">953<\/td><td class=\"k\">mouse xenograft model<\/td><td class=\"r\">3,801<\/td><td class=\"r\">4,098<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">954<\/td><td class=\"k\">anti-mrsa<\/td><td class=\"r\">1,216<\/td><td class=\"r\">1,296<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">955<\/td><td class=\"k\">laryngeal squamous cell<\/td><td class=\"r\">2,597<\/td><td class=\"r\">2,871<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">956<\/td><td class=\"k\">cancer development and progression<\/td><td class=\"r\">3,515<\/td><td class=\"r\">3,818<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">957<\/td><td class=\"k\">rectal cancer surgery<\/td><td class=\"r\">3,526<\/td><td class=\"r\">3,829<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">958<\/td><td class=\"k\">diabetes medications<\/td><td class=\"r\">1,106<\/td><td class=\"r\">1,163<\/td><td class=\"r\">18.9<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">959<\/td><td class=\"k\">brca2 gene<\/td><td class=\"r\">2,024<\/td><td class=\"r\">2,241<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">960<\/td><td class=\"k\">raf inhibitor<\/td><td class=\"r\">2,949<\/td><td class=\"r\">3,243<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">961<\/td><td class=\"k\">interferon-free<\/td><td class=\"r\">1,157<\/td><td class=\"r\">1,225<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">962<\/td><td class=\"k\">bovine respiratory disease<\/td><td class=\"r\">1,414<\/td><td class=\"r\">1,534<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">963<\/td><td class=\"k\">hiv-1 viral load<\/td><td class=\"r\">1,040<\/td><td class=\"r\">1,083<\/td><td class=\"r\">18.9<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">964<\/td><td class=\"k\">chronic kidney diseases<\/td><td class=\"r\">2,221<\/td><td class=\"r\">2,462<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">965<\/td><td class=\"k\">micrometastasis<\/td><td class=\"r\">2,654<\/td><td class=\"r\">2,933<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">966<\/td><td class=\"k\">lung cancer screening<\/td><td class=\"r\">3,548<\/td><td class=\"r\">3,852<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">967<\/td><td class=\"k\">ovarian cancer cell lines<\/td><td class=\"r\">3,312<\/td><td class=\"r\">3,616<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">968<\/td><td class=\"k\">alk inhibitor<\/td><td class=\"r\">1,477<\/td><td class=\"r\">1,609<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">969<\/td><td class=\"k\">braf v600e mutation<\/td><td class=\"r\">1,811<\/td><td class=\"r\">1,999<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">970<\/td><td class=\"k\">hiv-associated neurocognitive disorder<\/td><td class=\"r\">1,466<\/td><td class=\"r\">1,596<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">971<\/td><td class=\"k\">community-acquired pneumonia (cap)<\/td><td class=\"r\">4,496<\/td><td class=\"r\">4,759<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">972<\/td><td class=\"k\">carboplatin and paclitaxel<\/td><td class=\"r\">1,141<\/td><td class=\"r\">1,206<\/td><td class=\"r\">18.9<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">973<\/td><td class=\"k\">severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection<\/td><td class=\"r\">2,464<\/td><td class=\"r\">2,729<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">974<\/td><td class=\"k\">sw620<\/td><td class=\"r\">2,428<\/td><td class=\"r\">2,690<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">975<\/td><td class=\"k\">cancer symptom<\/td><td class=\"r\">1,725<\/td><td class=\"r\">1,900<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">976<\/td><td class=\"k\">tumor apoptosis<\/td><td class=\"r\">1,299<\/td><td class=\"r\">1,397<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">977<\/td><td class=\"k\">hcc risk<\/td><td class=\"r\">1,390<\/td><td class=\"r\">1,506<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">978<\/td><td class=\"k\">interstitial lung disease (ild)<\/td><td class=\"r\">3,910<\/td><td class=\"r\">4,207<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">979<\/td><td class=\"k\">multidrug-resistant tuberculosis<\/td><td class=\"r\">3,478<\/td><td class=\"r\">3,784<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">980<\/td><td class=\"k\">glargin<\/td><td class=\"r\">3,013<\/td><td class=\"r\">3,312<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">981<\/td><td class=\"k\">glycated haemoglobin (hba1c)<\/td><td class=\"r\">1,844<\/td><td class=\"r\">2,038<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">982<\/td><td class=\"k\">lung cancer screen<\/td><td class=\"r\">3,563<\/td><td class=\"r\">3,869<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">983<\/td><td class=\"k\">mcf-7 breast cancer cells<\/td><td class=\"r\">3,915<\/td><td class=\"r\">4,213<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">984<\/td><td class=\"k\">cardiovascular and cerebrovascular disease<\/td><td class=\"r\">1,978<\/td><td class=\"r\">2,191<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">985<\/td><td class=\"k\">non-small cell lung cancers<\/td><td class=\"r\">1,905<\/td><td class=\"r\">2,108<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">986<\/td><td class=\"k\">zikv infection<\/td><td class=\"r\">2,070<\/td><td class=\"r\">2,295<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">987<\/td><td class=\"k\">avian influenza virus (aiv)<\/td><td class=\"r\">1,189<\/td><td class=\"r\">1,265<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">988<\/td><td class=\"k\">epidermal growth factor receptor (egfr) mutations<\/td><td class=\"r\">1,072<\/td><td class=\"r\">1,123<\/td><td class=\"r\">18.9<\/td><td class=\"r\">95%<\/td><\/tr><tr><td class=\"r\">989<\/td><td class=\"k\">germline brca<\/td><td class=\"r\">1,236<\/td><td class=\"r\">1,322<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">990<\/td><td class=\"k\">5-year disease-free survival<\/td><td class=\"r\">2,758<\/td><td class=\"r\">3,046<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">991<\/td><td class=\"k\">breast cancer subtype<\/td><td class=\"r\">3,791<\/td><td class=\"r\">4,094<\/td><td class=\"r\">18.9<\/td><td class=\"r\">93%<\/td><\/tr><tr><td class=\"r\">992<\/td><td class=\"k\">tumor-node-metastasis (tnm)<\/td><td class=\"r\">1,145<\/td><td class=\"r\">1,212<\/td><td class=\"r\">18.9<\/td><td class=\"r\">94%<\/td><\/tr><tr><td class=\"r\">993<\/td><td class=\"k\">laboratory-confirmed influenza<\/td><td class=\"r\">994<\/td><td class=\"r\">1,028<\/td><td class=\"r\">18.9<\/td><td class=\"r\">97%<\/td><\/tr><tr><td class=\"r\">994<\/td><td class=\"k\">undetectable viral load<\/td><td class=\"r\">1,430<\/td><td class=\"r\">1,555<\/td><td class=\"r\">18.9<\/td><td class=\"r\">92%<\/td><\/tr><tr><td class=\"r\">995<\/td><td class=\"k\">high-fat diet-induced obesity<\/td><td class=\"r\">1,061<\/td><td class=\"r\">1,110<\/td><td class=\"r\">18.9<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">996<\/td><td class=\"k\">lung cancer diagnosis<\/td><td class=\"r\">1,683<\/td><td class=\"r\">1,853<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">997<\/td><td class=\"k\">cardiovascular disease prevention<\/td><td class=\"r\">2,177<\/td><td class=\"r\">2,416<\/td><td class=\"r\">18.9<\/td><td class=\"r\">90%<\/td><\/tr><tr><td class=\"r\">998<\/td><td class=\"k\">breast cancer gene<\/td><td class=\"r\">3,069<\/td><td class=\"r\">3,372<\/td><td class=\"r\">18.9<\/td><td class=\"r\">91%<\/td><\/tr><tr><td class=\"r\">999<\/td><td class=\"k\">asthma guidelines<\/td><td class=\"r\">1,056<\/td><td class=\"r\">1,104<\/td><td class=\"r\">18.9<\/td><td class=\"r\">96%<\/td><\/tr><tr><td class=\"r\">1000<\/td><td class=\"k\">asthma control questionnaire<\/td><td class=\"r\">966<\/td><td class=\"r\">994<\/td><td class=\"r\">18.9<\/td><td class=\"r\">97%<\/td><\/tr><\/tbody><\/table><\/div><\/section><nav class=\"kw-pager\"><a href=\"https:\/\/sustainability.uoa.edu.iq\/index.php\/sustainability-impact-network\/sdg-research-keywords\/sdg-02-research-keywords\/\"><i class=\"ds-ic\" style=\"--i:url(https:\/\/api.iconify.design\/lucide\/arrow-left.svg)\" aria-hidden=\"true\"><\/i><span><small style=\"display:block;font-weight:600;color:#64748b\">Previous goal<\/small>SDG 2: Zero Hunger<\/span><\/a><a class=\"up\" href=\"https:\/\/sustainability.uoa.edu.iq\/index.php\/sustainability-impact-network\/sdg-research-keywords\/\"><i class=\"ds-ic\" style=\"--i:url(https:\/\/api.iconify.design\/lucide\/layout-grid.svg)\" aria-hidden=\"true\"><\/i> All goals<\/a><a class=\"nx\" href=\"https:\/\/sustainability.uoa.edu.iq\/index.php\/sustainability-impact-network\/sdg-research-keywords\/sdg-04-research-keywords\/\"><span><small style=\"display:block;font-weight:600;color:#64748b\">Next goal<\/small>SDG 4: Quality Education<\/span><i class=\"ds-ic\" style=\"--i:url(https:\/\/api.iconify.design\/lucide\/arrow-right.svg)\" aria-hidden=\"true\"><\/i><\/a><\/nav><script>document.querySelectorAll(\".kw-q\").forEach(function(i){i.addEventListener(\"input\",function(){var q=i.value.trim().toLowerCase(),n=0,s=i.closest(\"section\");s.querySelectorAll(\"tbody tr\").forEach(function(r){var v=!q||r.children[1].textContent.toLowerCase().indexOf(q)>-1;r.hidden=!v;if(v)n++});s.querySelector(\".kw-n\").textContent=n})})<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Home\/Ranking\/Sustainability Impact Network\/SDG Research Keywords\/SDG 3 3Good Health and Well-being SDG 3: Good Health and Well-being \u2014 Research Keywords Research keywords that map publications to SDG 3 (Good Health and Well-being), from the Sustainability Research Mapping 2023 lists. 21 golden 100 in the Top 100 1,000 in the Top 1,000 On this pageGolden listTop 100Top &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/sustainability.uoa.edu.iq\/index.php\/sustainability-impact-network\/sdg-research-keywords\/sdg-03-research-keywords\/\"> <span class=\"screen-reader-text\">SDG 3: Good Health and Well-being \u2014 Research Keywords<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":9,"featured_media":0,"parent":9974,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-9986","page","type-page","status-publish","hentry"],"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"Dr.Alaa","author_link":"https:\/\/sustainability.uoa.edu.iq\/index.php\/author\/dr-ahmad\/"},"rttpg_comment":0,"rttpg_category":" <a href=\"https:\/\/sustainability.uoa.edu.iq\/\" rel=\"tag\">English<\/a>","rttpg_excerpt":"Home\/Ranking\/Sustainability Impact Network\/SDG Research Keywords\/SDG 3 3Good Health and Well-being SDG 3: Good Health and Well-being \u2014 Research Keywords Research keywords that map publications to SDG 3 (Good Health and Well-being), from the Sustainability Research Mapping 2023 lists. 21 golden 100 in the Top 100 1,000 in the Top 1,000 On this pageGolden listTop 100Top&hellip;","_links":{"self":[{"href":"https:\/\/sustainability.uoa.edu.iq\/index.php\/wp-json\/wp\/v2\/pages\/9986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sustainability.uoa.edu.iq\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sustainability.uoa.edu.iq\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sustainability.uoa.edu.iq\/index.php\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/sustainability.uoa.edu.iq\/index.php\/wp-json\/wp\/v2\/comments?post=9986"}],"version-history":[{"count":3,"href":"https:\/\/sustainability.uoa.edu.iq\/index.php\/wp-json\/wp\/v2\/pages\/9986\/revisions"}],"predecessor-version":[{"id":10124,"href":"https:\/\/sustainability.uoa.edu.iq\/index.php\/wp-json\/wp\/v2\/pages\/9986\/revisions\/10124"}],"up":[{"embeddable":true,"href":"https:\/\/sustainability.uoa.edu.iq\/index.php\/wp-json\/wp\/v2\/pages\/9974"}],"wp:attachment":[{"href":"https:\/\/sustainability.uoa.edu.iq\/index.php\/wp-json\/wp\/v2\/media?parent=9986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}